Novel functionalized lactones as serotonin receptor 7 modulators and methods of use thereof

By developing serotonin receptor 7 selective compounds with specific structures, the problem of insufficient selectivity of 5-HT7 receptor modulators in the prior art is solved, and effective targeting and treatment related to 5-HT7 receptors are achieved. The efficacy of the disease has been improved.

CN119060064APending Publication Date: 2024-12-03TEMPLE UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411125691.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-11-13
Filing Date
2020-11-12
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing serotonin receptor 7 modulators have insufficient selectivity and targeting in the treatment of related diseases, making it difficult to effectively target 5-HT7 receptors in specific tissues or organs.

Method used

A new class of compounds has a specific structure (such as formula (I*) and formula (I*-N) that can selectively target 5-HT7 receptors, including their enantiomers and diastereomers. , hydrates, solvates, pharmaceutically acceptable salts and complexes for the treatment of diseases associated with dysregulation of serotonin receptor 7 activity.

Benefits of technology

These compounds can effectively selectively regulate 5-HT7 receptors, improving the efficacy and safety of treating specific diseases, especially in the treatment of diseases related to 5-HT7 receptors such as inflammatory bowel disease and enteritis. They show excellent results in the treatment of diseases related to 5-HT7 receptors such as inflammatory bowel disease and enteritis .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060064A_ABST
    Figure CN119060064A_ABST
Patent Text Reader

Abstract

Described herein are novel selective modulators of the 5-HT7 receptor. These selective compounds are useful for the treatment of CNS and non-CNS indications. The compounds described herein may selectively target the 5-HT7 receptor, and / or by selectively targeting the 5-HT7 receptor expressed in certain tissues or organs, compared to other receptors, and thus may have effective selectivity in specific partition profiles of 5-HT7 modulators. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application is a divisional application of the Chinese invention patent application with application number 202080092891.1, application date November 12, 2020, and invention name "Novel functionalized lactones as serotonin receptor 7 modulators and methods of use thereof". The original application is a national phase application with international application number PCT / US2020 / 060271, which claims priority to U.S. provisional patent application No. 62 / 934,985 filed on November 13, 2019. The entire text of the provisional patent application is incorporated herein by reference.

[0003] Federally Sponsored Research Statement

[0004] This invention was made with government support under Grant No. 2R44DK115254-02A1 awarded by the National Institute of Diabetes and Digestive and Kidney Diseases. The government has certain rights in this invention. Background Art

[0005] Serotonin was discovered in the late 1940s and is present in the peripheral and central nervous systems [Physiol. Res, 60 (2011) 15-25; Psychopharmacology 213 (2011) 167-169]. Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter of the indolealkylamine group that acts on the synapses of nerve cells. Seven different serotonin receptor families have been discovered, and at least 20 subgroups have been cloned based on sequence similarity, signal transduction coupling and pharmacological characteristics. The seven 5-HT receptor families are named 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7, and each of these receptors has a subfamily or subgroup. The signal transduction mechanisms of all seven families have been studied, and it is known that activation of 5-HT1 and 5-HT5 receptors results in a decrease in intracellular cAMP, while activation of 5-HT2, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 results in an increase in intracellular IP3 and DAG. The 5-HT pathway in the brain is an important target for drug development in the field of CNS diseases. Neurotransmitters bind to their G protein-coupled receptors and participate in a variety of effects, including cognition, mood, anxiety, attention, appetite, cardiovascular function, vasoconstriction, sleep (ACS Medicinal Chemistry Letters, 2011, 2, 929-932; Physiological Research, 2011, 60, 15-25), inflammatory bowel disease (IBD) and enteritis (WO 2012058769, Khan, WI et al., Journal of Immunology, 2013, 190, 4795-4804), epilepsy, epilepsy (Epilepsy Research (2007) 75, 39), drug addiction and alcohol addiction (Hauser, SR et al., Frontiers in Neuroscience, 2015, 8, 1-9), etc.

[0006] New selective modulators of the 5-HT7 receptor are described herein. These selective compounds can be used to treat CNS and non-CNS indications. The compounds described herein can selectively target the 5-HT7 receptor compared to other receptors, and / or can have effective selectivity in a specific distribution spectrum of 5-HT7 modulators by selectively targeting the 5-HT7 receptor expressed in certain tissues or organs. Summary of the invention

[0007] In one aspect, the invention features a compound having a structure according to Formula (I*):

[0008]

[0009] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0010] R 1N Selected from the group consisting of: imidazole, oxazole, isoxazole in

[0011] Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0012] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0013] Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0014] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0015] R 8jSelected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0016] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0017] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0018] Each R AA are independently C1-C7 straight chain alkyl groups;

[0019] Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN;

[0020] a is 0, 1, or 2;

[0021] aa is 0, 1 or 2;

[0022] y 1 is 0, 1, or 2; and

[0023] When R 5 When it is an unsubstituted C1-C7 alkyl group or an unsubstituted C3-C7 cycloalkyl group, a is 1 or 2.

[0024] In another aspect, the invention features a compound having a structure according to Formula (I*-N):

[0025]

[0026] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0027] R 1N-N Selected from the group consisting of: C6-C 10 Heteroaryl, five- to ten-membered heteroaryl,

[0028]

[0029] Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4boptionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0030] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0031] Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0032] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0033] R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0034] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0035] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0036] Each R AA are independently C1-C7 straight chain alkyl groups;

[0037] Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN;

[0038] a is 0, 1, or 2;

[0039] aa is 0, 1 or 2;

[0040] y 1 is 0, 1, or 2; and

[0041] When R 5 When it is an unsubstituted C1-C7 alkyl group or an unsubstituted C3-C7 cycloalkyl group, a is 1 or 2.

[0042] In an embodiment, the compound of formula (I*) or (I*-N) has a structure according to formula -(I*-1),

[0043]

[0044] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

[0045] In an embodiment, the compound of formula (I*) or (I*-N) has a structure according to formula -(I*-2),

[0046]

[0047] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

[0048] In an embodiment, the compound of formula (I*-N) has a structure according to formula -(I*-3),

[0049]

[0050] Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

[0051] In an embodiment, R 1N for:

[0052] Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0053]

[0054] In an embodiment, R 1N for:

[0055] Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl;

[0056] Where R 8h is an unsubstituted C1-C7 alkyl group;

[0057] or

[0058]

[0059] In an embodiment, R 1N for:

[0060] Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl;

[0061] Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e is an unsubstituted C1-C7 alkyl group;

[0062] Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h is an unsubstituted C1-C7 alkyl group;

[0063]

[0064] Where R 8h is an unsubstituted C1-C7 alkyl group;

[0065] Each R 8a , R 8b , and R8g are independently H or unsubstituted C1-C7 alkyl, and R 8h is an unsubstituted C1-C7 alkyl group;

[0066] Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl;

[0067]

[0068] Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl;

[0069]

[0070] Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h are independently unsubstituted C1-C7 alkyl;

[0071] or

[0072]

[0073] In an embodiment, R 1N for:

[0074]

[0075] In an embodiment, R 1N for:

[0076]

[0077] In another aspect, the invention features a compound having a structure according to Formula (I**):

[0078]

[0079] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0080] Each R aa and R bb selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 branched alkyl;

[0081] Each R AA are independently C1-C7 straight chain alkyl groups;

[0082] Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN;

[0083] aa is 0, 1, or 2; and

[0084] a' is 1 or 2.

[0085] In an embodiment, R aa and R bb Each is an ethyl group.

[0086] In an embodiment, a is 0 or 1.

[0087] In an embodiment, a is 1 or 2, and each R AA It is methyl.

[0088] In an embodiment, a' is 1 or 2, and each R AA It is methyl.

[0089] In an embodiment, aa is 0 or 1.

[0090] In an embodiment, each R 2a are independently halogen.

[0091] In an embodiment, each R 2a is independently –F or –Cl.

[0092] In an embodiment, the C5 carbon of the 2-dihydrofuranone has the (R)-configuration.

[0093] In an embodiment, the C5 carbon of the 2-dihydrofuranone has the (R)-configuration.

[0094] In another aspect, the invention features a compound having a structure according to formula (I)

[0095]

[0096] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0097] Each R a and R b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 branched alkyl; or R a and R b Together with the atoms to which they are attached, they form a carbocyclic ring having 5 to 7 ring atoms, optionally containing a double bond; or R a and R bTogether with the atoms to which they are attached, they form a ring having 6-8 ring atoms, the ring comprising a member selected from O, S, SO, SO2 and NR 1 part of;

[0098] A is an N-linked five to twelve membered nitrogen-containing heterocyclic group, wherein the nitrogen-containing heterocyclic group is bicyclic or polycyclic and optionally contains other heteroatoms selected from O, N and S, and wherein the non-aromatic nitrogen-containing heterocyclic group further contains a group R 2 ;

[0099] R 1 is H, C1-C7 alkyl, C3-C7 cycloalkyl, phenyl, benzyl, a five-membered to six-membered heteroaryl ring, a polar acyl group or a polar sulfonyl group;

[0100] R 2 is selected from the group consisting of a 6- to 10-membered aryl group, a 5- to 10-membered nitrogen-containing heteroaryl group, and

[0101] R 3 is a 6- to 10-membered aryl group or a 5- to 10-membered nitrogen-containing heteroaryl group;

[0102] m is 1, 2 or 3; and

[0103] n is 1, 2, 3 or 4; and

[0104] When A is 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, octahydropyrrolo[3,4-c]pyrrol-1-yl or 2,6-diazaspiro[3.3]hept-1-yl, then R a and R b cannot be all methyl, all ethyl, or all phenyl, and R a and R b Nor can they combine to form unsubstituted C3-C6 cycloalkyl groups.

[0105] In an embodiment of formula (I), R a and R b Together with the atoms to which they are attached, they form a ring having 6 to 8 ring atoms, wherein one of the ring atoms is selected from the group consisting of: O, S, SO, SO2 and NR 1 .

[0106] In an embodiment, the compound of formula (I) has one of the following structures:

[0107]

[0108] In an embodiment of formula (I), R a and R b are methyl or ethyl, or Ra and R b Combine to form unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0109] In an embodiment, the compound of formula (I) has one of the following structures:

[0110]

[0111] In an embodiment, the compound of formula (I) conforms to one of the following structures:

[0112]

[0113]

[0114] In an embodiment of formula (I), R a and R b Together with the atoms to which they are bound they form a ring having 6 to 8 ring atoms.

[0115] In an embodiment, the compound of formula (I) has a structure according to formula-(IF),

[0116] In an embodiment, the compound of formula (I) has a structure according to one of the following formulae:

[0117]

[0118] In an embodiment of formula (I), A is selected from the group consisting of:

[0119]

[0120]

[0121] in

[0122] R 2 Selected from the group consisting of phenyl, naphthyl, pyridyl, indolyl and

[0123] R 3 selected from the group consisting of phenyl, naphthyl, pyridyl and indolyl;

[0124] R ASelected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl , carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; and

[0125] a is 0, 1 or 2.

[0126] In an embodiment of formula (I), A is selected from the group consisting of:

[0127]

[0128]

[0129] In an embodiment of formula (I), A is selected from the group consisting of:

[0130]

[0131] In an embodiment of formula (I), a is 0. In an embodiment of formula (I), a is 1. In an embodiment of formula (I), a is 2.

[0132] In an embodiment of formula (I), R 1 Selected from the group consisting of: H, C1-C7 alkyl, C3-C7 cycloalkyl, phenyl, benzyl, imidazole, oxazole, isoxazole,

[0133] Each R 4a ,R 4b ,R 4c ,R 6a ,R 6b and R 6c selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0134] R 4a and R 4boptionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0135] R 6a and R 6b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0136] Each R 4d and R 6d Selected from the group consisting of phenyl, benzyl, pyridyl, -CH2(pyridyl), imidazole and -CH2(imidazole).

[0137] R 5 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0138]

[0139] R 7 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NHCONR 8f ;

[0140] Each R 8a , R 8b , R 8d , R 8 and R 8i gselected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0141] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0142] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0143] R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0144] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0145] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0146] R 11 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0147] y 1 is 0, 1, or 2; and

[0148] y 2 Is 0, 1, or 2.

[0149] In an embodiment of formula (I), R 1 Selected from the group consisting of:

[0150]

[0151] In an embodiment of formula (I), R 1 Selected from the group consisting of:

[0152] COOR 5 , where R 5 C6-C 10 Aryl or 5- to 10-membered heteroaryl;

[0153] Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0154] Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl;

[0155] Where R 8h is an unsubstituted C1-C7 alkyl group;

[0156] Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl;

[0157] Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl;

[0158] Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e is an unsubstituted C1-C7 alkyl

[0159] Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h is an unsubstituted C1-C7 alkyl group;

[0160]

[0161] Where R 8h is an unsubstituted C1-C7 alkyl group;

[0162] Each R 8a , R 8b and R 8gare independently H or unsubstituted C1-C7 alkyl, and R 8h is an unsubstituted C1-C7 alkyl group;

[0163]

[0164]

[0165] Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl;

[0166]

[0167] Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h are independently unsubstituted C1-C7 alkyl; or

[0168]

[0169] In another aspect, the invention features a compound according to formula (II),

[0170]

[0171] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0172] A 2 for

[0173] R 2 is selected from the group consisting of a 6- to 10-membered aryl group, a 5- to 10-membered nitrogen-containing heteroaryl group, and

[0174] R 3 is a 6- to 10-membered aryl group or a 5- to 10-membered nitrogen-containing heteroaryl group;

[0175] R ASelected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl alkyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups each containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen;

[0176] a is 0, 1, or 2;

[0177] m is 1, 2 or 3;

[0178] n is 1, 2, 3 or 4;

[0179] R 1’ Selected from the group consisting of: C6-C 10 Aryl, five-membered to six-membered heteroaryl ring,

[0180]

[0181] Each R 4a ,R 4b ,R 4c ,R 6a ,R 6b and R 6c selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0182] R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0183] R 6a and R 6b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0184] Each R 4d and R 6d Selected from the group consisting of phenyl, benzyl, pyridyl, -CH2(pyridyl), imidazole and -CH2(imidazole).

[0185] R 5 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0186]

[0187] R 7 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NHCONR 8f ;

[0188] Each R 8a , R 8b , R 8d , R 8g and R 8i selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0189] R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0190] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0191] Each R8c , R 8e , R 8f and R 8h is C1-C7 alkyl or C3-C7 cycloalkyl; or

[0192] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0193] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0194] R 11 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0195] y 1 is 0, 1, or 2; and

[0196] y 2 is 0, 1, or 2; and

[0197] Among them, when A 2 for R 2 is phenyl, R 1’ for y 2 When is 0 and n is 2, then R 7 It is not methyl, CH2SO2CH3, CH2CN, tetrahydropyranyl, phenyl, 4-substituted phenyl or 5- to 8-membered heteroaryl.

[0198] In an embodiment, the compound according to formula (II) has one of the following structures:

[0199]

[0200] In the embodiment of formula (II), R 1’ for:

[0201] COOR 5 , where R 5 C6-C 10 Aryl or 5- to 10-membered heteroaryl;

[0202] Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8boptionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0203] Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl;

[0204] Where R 8h is an unsubstituted C1-C7 alkyl group;

[0205] Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl;

[0206] Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl;

[0207] Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e is an unsubstituted C1-C7 alkyl

[0208] Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h is an unsubstituted C1-C7 alkyl group;

[0209]

[0210] Where R 8h is an unsubstituted C1-C7 alkyl group;

[0211] Each R 8a , R 8b and R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h is an unsubstituted C1-C7 alkyl group;

[0212]

[0213]

[0214] Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl;

[0215]

[0216] Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h are independently unsubstituted C1-C7 alkyl; or

[0217]

[0218] In the embodiment of formula (II), A 2 for

[0219] In the embodiment of formula (II), A 2 for

[0220] In the embodiment of formula (II), A 2 for

[0221] In an embodiment, the compound of formula (I), (I*), (I**) or (II) is any one of compounds 1-145, including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

[0222] In another aspect, the invention features a pharmaceutical composition including any of the compounds described herein (eg, a compound according to Formula (I), (I*), (I**), or (II)), or a pharmaceutically acceptable salt thereof.

[0223] In an embodiment, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

[0224] In another aspect, the invention features a method of treating a disease associated with dysregulated serotonin receptor 7 activity, the method comprising administering to a subject an effective amount of at least one compound as described herein (e.g., a compound according to Formula (I), (I*), (I**), or (II)) or a pharmaceutically acceptable salt thereof.

[0225] In an embodiment, the at least one compound or a pharmaceutically acceptable salt thereof is administered in a composition further comprising at least one excipient.

[0226] In an embodiment, the disease associated with dysregulation of serotonin receptor 7 activity is selected from the group consisting of peripheral selective diseases, nervous system diseases, circadian rhythm disorders, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral vascular disease, migraine, neuropathic pain, peripheral pain, allodynia, temperature regulation disorders, learning disorders, memory disorders, hippocampal signaling disorders, sleep disorders, attention deficit / hyperactivity disorder, anxiety disorders, avoidant personality disorder, premature ejaculation, eating disorders, premenstrual syndrome, premenstrual dysphoric disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), enteritis, epilepsy, epilepsy, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestinal neuroendocrine tumors and lung injury.

[0227] In an embodiment, the disease associated with dysregulation of serotonin receptor 7 activity is inflammatory bowel disease (IBD) or inflammatory bowel disease. DETAILED DESCRIPTION

[0228] definition

[0229] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or test of the present invention, exemplary methods, devices and materials are now described. All technical and patent publications cited herein are incorporated herein by reference in their entirety. Nothing herein should be construed as admitting that the present invention is not entitled to be disclosed earlier than these by virtue of prior inventions.

[0230] As used throughout the specification, when a composition is described as having, including, or comprising particular components, or when a method is described as having, including, or comprising particular method steps, it is contemplated that the compositions of the present teachings also consist essentially of or consist of the enumerated components, and that the methods of the present teachings also consist essentially of or consist of the enumerated method steps.

[0231] Throughout this application, where an element or component is referred to as being included in and / or selected from the listed elements or components, it should be understood that the element or component may be any one of the listed elements or components, and may be selected from two or more of the listed elements or components.

[0232] Unless expressly stated otherwise, the use of the singular herein includes the plural (and vice versa). In addition, when the term "about" is used before a quantitative value, the present teachings also include the specific quantitative value itself, unless expressly stated otherwise.

[0233] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present teachings are still operable. In addition, two or more steps or actions may be performed simultaneously.

[0234] As used herein, the term "halogen" shall mean chlorine, bromine, fluorine and iodine.

[0235] As used herein, unless otherwise specified, "alkyl" and / or "aliphatic", whether used alone or as part of a substituent group, refers to straight and branched carbon chains having 1 to 20 carbon atoms or any number within this range (e.g., 1 to 6 carbon atoms or 1 to 4 carbon atoms). The specified number of carbon atoms (e.g., C1-C6) should independently refer to the number of carbon atoms in the alkyl portion or to the number of carbon atoms in the alkyl portion of a larger alkyl-containing substituent. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like. Alkyl groups may be unsubstituted or substituted, including substitution by any substituent and combination of substituents described herein. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, 3-carboxypropyl, and the like. In a substituent having multiple alkyl groups, such as (C1-C6 alkyl)2amino, the alkyl groups may be the same or different.

[0236] As used herein, the term "alkenyl" and "alkynyl" groups, whether used alone or as part of a substituent group, refer to straight and branched carbon chains with 2 or more, preferably 2 to 20 carbon atoms, wherein the alkenyl chain has at least one double bond in the chain, and the alkynyl chain has at least one triple bond in the chain. Alkenyl and alkynyl can be unsubstituted or substituted. Non-limiting examples of alkenyl groups include vinyl, 3-propenyl, 1-propenyl (also 2-methylvinyl), isopropenyl (also 2-methylvinyl-2-yl), butene-4-yl, etc. Non-limiting examples of substituted alkenyl groups include 2-chlorovinyl (also 2-chlorovinyl), 4-hydroxybutene-1-yl, 7-hydroxy-7-methyloct-4-ene-2-yl, 7-hydroxy-7-methyloct-3,5-diene-2-yl, etc. The limiting examples of alkynyl groups include ethynyl, prop-2-ynyl (also propargyl), propyn-1-yl and 2-methyl-hex-4-yn-1-yl. The limiting examples of substituted alkynyl groups include 5-hydroxy-5-methyl hex-3-ynyl, 6-hydroxy-6-methyl hept-3-yn-2-yl, 5-hydroxy-5-ethyl hept-3-yn-yl etc.

[0237] As used herein, "cycloalkyl", whether used alone or as part of another group, refers to a non-aromatic carbon-containing ring containing, for example, 3 to 14 ring carbon atoms, preferably 3 to 7 or 3 to 6 ring carbon atoms, or even 3 to 4 ring carbon atoms, alkylene and alkynyl groups and optionally containing one or more (e.g., 1, 2 or 3) double or triple bonds. The cycloalkyl group can be monocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused, bridged and / or spirocyclic systems), wherein the carbon atoms are located inside or outside the ring system. Any suitable ring position of the cycloalkyl group can be covalently attached to a defined chemical structure. The cycloalkyl ring can be unsubstituted or substituted. Non-limiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulyl; bicyclo[6.2.0]decyl, decahydronaphthyl and dodecahydro-1H-fluorenyl. The term "cycloalkyl" also includes carbocycles that are bicyclic hydrocarbon rings, non-limiting examples of which include bicyclo-[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, 1,3-dimethyl[2.2.1]hept-2-yl, bicyclo[2.2.2]octyl, and bicyclo[3.3.3]undecyl.

[0238] "Haloalkyl" is intended to include branched and straight chain saturated aliphatic hydrocarbon groups with a specified number of carbon atoms substituted by one or more halogens.Haloalkyl groups include perhaloalkyl groups, in which all hydrogens of the alkyl group have been replaced by halogens (e.g., -CF3, -CF2CF3). In addition to halogen, haloalkyl may also be optionally substituted by one or more substituents. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl and pentachloroethyl groups.

[0239] The term "alkoxy" refers to group-O-alkyl, wherein the alkyl group is as defined above. The alkoxy group may optionally be substituted. The term C3-C6 cycloalkoxy refers to a ring containing 3 to 6 carbon atoms and at least one oxygen atom (e.g., tetrahydrofuran, tetrahydro-2H-pyrans). The C3-C6 cycloalkoxy may optionally be substituted.

[0240] The term "haloalkoxy" refers to the group -O-haloalkyl, wherein the haloalkyl group is as defined above. Examples of haloalkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and pentafluoroethoxy.

[0241] The term "aryl" used alone or as part of another group is defined herein as an unsaturated aromatic monocyclic ring of 6 carbon members or an unsaturated aromatic polycyclic ring containing 6 to 14 carbon members. The aryl group can be unsubstituted or substituted. The aryl ring can be, for example, a benzene ring or a naphthalene ring optionally substituted by one or more parts capable of replacing one or more hydrogen atoms. Non-limiting examples of aryl groups include: phenyl, naphthalene-1-yl, naphthalene-2-yl, 4-fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl, 2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert-butylphenyl, 3-methoxyphenyl, 8-hydroxynaphthalene-2-yl-4,5-dimethoxynaphthalene-1-yl and 6-cyano-naphthalene-1-yl. Aryl groups also include, for example, a benzene or naphthalene ring fused to one or more saturated or partially saturated carbocyclic rings (e.g., bicyclo[4.2.0]octa-1,3,5-trienyl, indanyl), which may be substituted at one or more carbon atoms of the aromatic ring and / or the saturated or partially saturated ring.

[0242] The term "arylalkyl" or "aralkyl" refers to the group -alkyl-aryl, wherein the alkyl and aryl groups are as defined herein. The aralkyl groups of the present invention are optionally substituted. Examples of aralkyl groups include, for example, benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl, etc.

[0243] The term "heterocycle" and / or "heterocyclyl", whether used alone or as part of another group, is defined herein as one or more rings having 3 to 20 atoms, wherein at least one atom in at least one ring is a heteroatom selected from nitrogen (N), oxygen (O) or sulfur (S), and the ring containing the heteroatom is non-aromatic. In a heterocyclic group comprising 2 or more fused rings, the ring with the non-heteroatom may be an aryl (e.g., indolinyl, tetrahydroquinolinyl, chromanyl). Exemplary heterocyclic groups have 3 to 14 ring atoms, of which 1 to 5 are heteroatoms independently selected from nitrogen (N), oxygen (O) or sulfur (S). One or more N or S atoms in a heterocyclic group may be oxidized. A heterocyclic group may be unsubstituted or substituted.

[0244] Non-limiting examples of heterocyclic units having a single ring include: bisaziridinyl, aziridinyl, urazolyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolidinyl, isothiazolyl, isothiazolinyl, oxathiazolidinone, oxazolidinone, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-one (valerolactam), 2,3,4,5-tetrahydro-1H-azepinyl, 2,3-dihydro-1H-indole, and 1,2,3,4-tetrahydro-quinoline. Non-limiting examples of heterocyclic units having 2 or more rings include: hexahydro-1H-pyrrolazinyl, 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl, chromanyl, isochromanyl, indolinyl, isoindolyl, and decahydro-1H-cycloocta[b]pyrrolyl.

[0245] The term "heteroaryl", whether used alone or as part of another group, is defined herein as one or more rings having 5 to 20 atoms, wherein at least one atom in at least one ring is a heteroatom selected from nitrogen (N), oxygen (O) or sulfur (S), and at least one of the rings containing heteroatoms is aromatic. In heteroaryl groups containing 2 or more fused rings, the ring with non-heteroatoms may be a carbocycle (e.g., 6,7-dihydro-5H-cyclopentylpyrimidine) or an aryl (e.g., benzofuranyl, benzothienyl, indolyl). Exemplary heteroaryl groups have 5 to 14 ring atoms and contain 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O) or sulfur (S). One or more N or S atoms in the heteroaryl group may be oxidized. The heteroaryl group may be unsubstituted or substituted. Non-limiting examples of heteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, furanyl, thienyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl and 4-dimethylaminopyridinyl. Non-limiting examples of heteroaryl rings containing 2 or more fused rings include benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, 1H-benzo[d]imidazol-2(3H)-onyl, 1H-benzo[d]imidazolyl, and isoquinolinyl.

[0246] A non-limiting example of a heteroaryl group as described above is a C1-C5 heteroaryl group having 1 to 5 carbon ring atoms and at least one other ring atom (preferably 1 to 4 other ring atoms as heteroatoms) independently selected from nitrogen (N), oxygen (O) or sulfur (S). Examples of C1-C5 heteroaryl groups include, but are not limited to, triazine, thiazol-2-yl, thiazol-4-yl, imidazole-1-yl, 1H-imidazole-2-yl, 1H-imidazole-4-yl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-4-yl, pyrimidine-2-yl, pyrimidine-4-yl, pyrimidine-5-yl, pyridin-2-yl, pyridin-3-yl and pyridin-4-yl.

[0247] Unless otherwise indicated, when two substituents are taken together to form a ring having the indicated number of ring atoms (e.g., R 2 and R 3When taken together with the nitrogen (N) to which they are attached to form a ring having 3 to 7 ring members, the ring may have carbon atoms and optionally one or more (e.g., 1 to 3) additional heteroatoms independently selected from nitrogen (N), oxygen (O) or sulfur (S). The ring may be saturated or partially saturated and may be optionally substituted.

[0248] For the purposes of this invention, fused ring units containing a single heteroatom, as well as spirocyclic rings, bicyclic rings, etc., will be considered to belong to the cyclic family corresponding to the heteroatom-containing ring. For example, for the purposes of this invention, 1,2,3,4-tetrahydroquinoline having the formula:

[0249]

[0250] For the purposes of the present invention, 6,7-dihydro-5H-cyclopentylpyrimidine has the following formula:

[0251]

[0252] is considered a heteroaryl unit. When a fused ring unit contains heteroatoms in both the saturated and aryl rings, the aryl ring will predominate and be determined as the type of class specified for the ring. For example, for the purposes of this invention, 1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula:

[0253]

[0254] are considered to be heteroaryl units.

[0255] Whenever a term or any of its prefix roots appear in the name of a substituent, the name should be interpreted as including those limitations provided herein. For example, whenever the term "alkyl" or "aryl" or any of their prefix roots appear in the name of a substituent (e.g., arylalkyl, alkylamino), the name should be interpreted as including those limitations given above for "alkyl" and "aryl".

[0256] The term "substituted" is used throughout the specification. The term "substituted" is defined herein as a portion having one or more hydrogen atoms replaced by one or more (e.g., 1 to 10) substituents as defined below, whether acyclic or cyclic. Substituents can replace one or two hydrogen atoms of a single portion at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form the substituent, new portion or unit. For example, the substitution unit requiring a single hydrogen atom replacement includes halogen, hydroxyl, etc. Two hydrogen atom replacements include carbonyl, oxime, etc. Two hydrogen atom replacements from adjacent carbon atoms include epoxy resins, etc. The term "substituted" is used throughout the specification to indicate that a portion may have one or more hydrogen atoms replaced by a substituent. When a portion is described as "substituted", any number of hydrogen atoms can be replaced. For example, difluoromethyl is a substituted C1 alkyl; trifluoromethyl is a substituted C1 alkyl; 4-hydroxyphenyl is a substituted aromatic ring; (N,N-dimethyl-5-amino)octyl is a substituted C8 alkyl; 3-guanidinopropyl is a substituted C3 alkyl; and 2-carboxypyridyl is a substituted heteroaryl.

[0257] Variable groups as defined herein (e.g., alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle, and heteroaryl groups as defined herein), whether used alone or as part of another group, may be optionally substituted. Optionally substituted groups will be indicated as such.

[0258] The following are non-limiting examples of substituents for substituting hydrogen atoms on a substitutable moiety: halogen (chlorine (Cl), bromine (Br), fluorine (F), and iodine (I)), –CN, –NO2, oxo (═O), –OR′, –SR′, –N(R′)2, –NR′C(O)R′, –SO2R′, –SO2OR′, –SO2N(R′)2, –C(O)R′, –C(O)OR′, –C(O)N(R′)2, C1–C6 alkyl, C1–C6 haloalkyl, C1–C6 alkoxy, C2–C8 alkenyl, C2–C8 alkynyl, C3–C 14cycloalkyl, aryl, heterocycle or heteroaryl, wherein each of alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocycle and heteroaryl is optionally substituted with 1-10 (e.g., 1-6 or 1-4) groups independently selected from halogen, -CN, -NO2, oxo and R'; wherein R' is independently hydrogen, -OR", -SR", -C(O)R", -C(O)OR", -C(O)N(R")2, -SO2R", -S(O)2OR", -N(R")2, -NR"C(O)R", C1-C6 alkyl, C1-C6 haloalkyl, C2-C8 alkenyl , C2-C8 alkynyl, cycloalkyl (e.g. C3-C6 cycloalkyl), aryl, heterocycle or heteroaryl, or two R' units together with the atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring has 3 to 7 ring atoms; wherein R" at each occurrence is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, cycloalkyl (e.g. C3-C6 cycloalkyl), aryl, heterocycle or heteroaryl, or two R" units together with the atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring preferably has 3 to 7 ring atoms.

[0259] In some embodiments, the substituent is selected from

[0260] i) –OR’”; for example, –OH, –OCH3, –OCH2CH3, –OCH2CH2CH3;

[0261] ii) –C(O)R'”; for example, –COCH3, –COCH2CH3, –COCH2CH2CH3;

[0262] iii) –C(O)OR'"; for example, –CO2CH3, –CO2CH2CH3, –CO2CH2CH2CH3;

[0263] iv) –C(O)N(R'")2; for example, –CONH2, –CONHCH3, –CON(CH3)2;

[0264] v) –N(R'")2; for example, –NH2, –NHCH3, –N(CH3)2, –NH(CH2CH3);

[0265] vi) Halogens: –F, –Cl, –Br and –I;

[0266] vii) – CH e X g ; wherein X is a halogen, m is 0 to 2, and e+g=3; for example, –CH2F, –CHF2, –CF3, –CCl3, or –CBr3;

[0267] viii) –SO2R'"; for example, –SO2H; –SO2CH3; –SO2C6H5;

[0268] ix) C1-C6 straight chain, branched or cyclic alkyl;

[0269] x) Cyano

[0270] xi) nitro;

[0271] xii) N(R'')C(O)R'';

[0272] xiii) oxo (=O);

[0273] xiv) a heterocyclic ring; and

[0274] xv) heteroaryl.

[0275] wherein each R'" is independently hydrogen, optionally substituted C1-C6 straight or branched alkyl (e.g., optionally substituted C1-C4 straight or branched alkyl), or optionally substituted C3-C6 cycloalkyl (e.g., optionally substituted C3-C4 cycloalkyl); or two R'" units can be taken together to form a ring containing 3-7 ring atoms. In certain aspects, each R'" is independently hydrogen, C1-C6 straight or branched alkyl optionally substituted by halogen or C3-C6 cycloalkyl, or C3-C6 cycloalkyl.

[0276] At various places in this specification, substituents of compounds are disclosed in the form of groups or ranges. Specifically, the description includes every individual subcombination of members in these groups and ranges. For example, the term "C 1–6 The term “alkyl” is specifically intended to disclose individually C1, C2, C3, C4, C5, C6, C1-C6, C1–C5, C1–C4, C1–C3, C1–C2, C2–C6, C2–C5, C2–C4, C2–C3, C3–C6, C3–C5, C3–C4, C4–C6, C4–C5, and C5–C6 alkyl.

[0277] For the purposes of the present invention, the terms "compound", "analog" and "composition of matter" also represent the 5-hydroxytryptamine receptor 7 activity modulators described herein, including all enantiomeric forms, diastereomeric forms of salts, etc., and the terms "compound", "analog" and "composition of matter" can be used interchangeably in this specification.

[0278] The compounds described herein may contain asymmetric atoms (also referred to as chiral centers), and some compounds may contain one or more asymmetric atoms or centers, thus producing optical isomers (enantiomers) and diastereomers. The present teachings and compounds disclosed herein include such enantiomers and diastereomers, as well as racemic and resolved enantiomerically pure R and S stereoisomers, and other mixtures of R and S stereoisomers and pharmaceutically acceptable salts thereof. For example, certain gamma-butyrolactones containing substituents on the C5 carbon of a heterocycle are described herein. In embodiments of any compound or formula described herein, the C5 carbon has an (S)-configuration. In embodiments of any compound or formula described herein, the C5 carbon has an (R)-configuration. Optical isomers can be obtained in pure form by standard procedures known to those skilled in the art, including, but not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. The present teachings also encompass cis- and trans-isomers of compounds containing alkenyl moieties (e.g., alkenes and imines). It is also to be understood that the present teachings encompass all possible regioisomers and mixtures thereof, which can be obtained in pure form by standard separation procedures known to those skilled in the art including, but not limited to, column chromatography, thin layer chromatography, and high performance liquid chromatography.

[0279] Organic bases and inorganic bases can be used to form pharmaceutically acceptable salts of the compounds of the present teachings, which may have an acidic part. Monoanionic salts and polyanionic salts can be envisioned, depending on the number of acidic hydrogens that can be used for deprotonation. Suitable salts formed with alkalis include metal salts, such as alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts or magnesium salts; Ammonia salts and organic amine salts, such as morpholine, thiomorpholine, piperidine, pyrrolidine, mono, di or tri-lower alkylamines (e.g., ethyl-tert-butylamine, diethylamine, diisopropylamine, triethylamine, tributylamine or dimethylpropylamine), or monohydroxy, dihydroxy or trihydroxy lower alkylamines (e.g., monoethanolamine, diethanolamine or triethanolamine). The specific non-limiting examples of inorganic bases include NaHCO3, Na2CO3, KHCO3, K2CO3, Cs2CO3, LiOH, NaOH, KOH, NaH2PO4, Na2HPO4 and Na3PO4. Internal salts can also be formed. Similarly, when the compounds disclosed herein contain a basic moiety, organic and inorganic acids can be used to form salts. For example, salts can be formed from the following acids: acetic acid, propionic acid, lactic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, tartaric acid, succinic acid, dichloroacetic acid, vinylsulfonic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalenesulfonic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phosphoric acid, phthalic acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, toluenesulfonic acid and camphorsulfonic acid, as well as other known pharmaceutically acceptable acids.

[0280] When any variable occurs more than one time in any constituent or in any formula, its definition on each occurrence is independent of its definition at all other occurrences (e.g., in N(R 9 )2, each R 9 Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.

[0281] As used herein, the term "treat" refers to partially or completely alleviating, inhibiting, ameliorating and / or relieving a condition that a patient is suspected of suffering from.

[0282] As used herein, "therapeutically effective" and "effective dose" refer to a substance or amount that elicits a desired biological activity or effect.

[0283] Unless otherwise indicated, the terms "subject" or "patient" are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats and mice, and other animals. Therefore, the terms "subject" or "patient" as used herein mean any mammalian patient or subject to which the compounds of the present invention can be administered. In an exemplary embodiment of the present invention, in order to identify a subject to be treated according to the method of the present invention, a recognized screening method is used to determine the risk factors associated with a targeted or suspected disease or condition or to determine the status of an existing disease or condition in the subject. These screening methods include, for example, routine examinations to determine the risk factors that may be associated with a targeted or suspected disease or condition. These and other conventional methods enable clinicians to select patients in need of treatment using the methods and compounds of the present invention.

[0284] 5-HT receptor 7 activity modulators

[0285] 5-HT7 activity modulators

[0286] Described herein are lactone compounds that can modulate the activity of 5-hydroxy receptor 7 (5-HT7). In particular, the compounds described herein can be selective modulators of the 5-HT7 receptor. In embodiments, selectively modulating 5-HT7 includes selectively modulating 5-HT7 compared to other receptors. In embodiments, selectively modulating 5-HT7 includes selectively modulating 5-HT7 expressed in, for example, a specific organ or tissue. Thus, the compounds described herein can be used to treat a variety of diseases and conditions (e.g., as described herein).

[0287] In embodiments of any formula described herein, C1-C7 alkyl is C1-C7 straight chain alkyl. In embodiments, C1-C7 alkyl is unsubstituted C1-C7 straight chain alkyl. In embodiments, C1-C7 alkyl is unsubstituted C1-C7 straight chain alkyl (e.g., substituted by 1, 2, 3 or more substituents as described herein). In embodiments, substituted C1-C7 straight chain alkyl is C1-C7 straight chain perhaloalkyl (e.g., perfluoroalkyl). In embodiments, substituted C1-C7 straight chain alkyl comprises 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of C1-C7 alkyl are described herein.

[0288] In embodiments of any formula described herein, C1-C7 alkyl is C3-C7 branched alkyl. In embodiments, C3-C7 branch is unsubstituted C3-C7 branched alkyl. In embodiments, C3-C7 branch is unsubstituted C3-C7 branch (e.g., substituted by 1, 2, 3 or more substituents as described herein). In embodiments, substituted C3-C7 branch is C3-C7 branch perhaloalkyl (e.g., perfluoroalkyl). In embodiments, substituted C3-C7 branch comprises 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of C3-C7 branched alkyl are described herein.

[0289] In embodiments of any formula described herein, cycloalkyl is C3-C7 or C3-C8 cycloalkyl. In embodiments, cycloalkyl is cyclopropyl. In embodiments, cycloalkyl is cyclobutyl. In embodiments, cycloalkyl is cyclopentyl. In embodiments, cycloalkyl is cyclohexyl. In embodiments, cycloalkyl is unsubstituted cycloalkyl (e.g., unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl). In embodiments, cycloalkyl is substituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which contains 1, 2, 3, 4 or 5 substituents, including the exemplary substituents described herein). In embodiments, substituted cycloalkyl contains 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of cycloalkyl are also described herein.

[0290] In any of the embodiments described herein, C6-C 10 Aryl is phenyl. In embodiments, phenyl is unsubstituted phenyl. In embodiments, phenyl is unsubstituted phenyl (e.g., phenyl comprising 1, 2, 3, 4 or 5 substituents, the substituents including exemplary substituents as described herein). Substituted phenyl can be connected via any available carbon of the ring, including as described herein. For example, phenyl can have substituents as described herein (e.g., OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2), which are in the para position (e.g., 4-substituted phenyl) of the molecular attachment point. In embodiments, phenyl can have substituents as described herein (e.g., OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2), which are in the meta position (e.g., 3-substituted phenyl) of the molecular attachment point. In embodiments, the phenyl group may have a substituent as described herein (e.g., OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3, and CO2NH2) in an ortho position to the point of attachment of the molecule (e.g., 2-substituted phenyl). The phenyl group may have two or more (e.g., 2,3-disubstituted, 2,4-disubstituted, 2,5-disubstituted, 2,6-disubstituted, 3,4-disubstituted, or 3,5-disubstituted phenyl) or three or more substituents (e.g., 2,3,4-trisubstituted, 2,3,5-trisubstituted, 2,3,6-trisubstituted, 2,4,5-trisubstituted, 2,4,6-trisubstituted, 3,4,5-trisubstituted, or 3,4,6-trisubstituted). In an embodiment, the substituted phenyl comprises 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of phenyl are described herein. In an embodiment, phenyl is unsubstituted phenyl, 4-OH-phenyl, 3-OH-phenyl, 2-OH-phenyl, 4-OMe-phenyl, 3-OMe-phenyl, 2-OMe-phenyl, 4-CN-phenyl, 3-CN-phenyl, 2-CN-phenyl, 4-Me-phenyl, 3-Me-phenyl, 2-Me-phenyl, 4-Et-phenyl, 3-Et-phenyl, 2-Et-phenyl, 4- i Pr-phenyl, 3- i Pr-phenyl, 2- iPr-phenyl, 4-F-phenyl, 3-F-phenyl, 2-F-phenyl, 4-Cl-phenyl, 3-Cl-phenyl, 2-Cl-phenyl, 4-Br-phenyl, 3-Br-phenyl, 2-Br-phenyl, 4-NH2-phenyl, 3-NH2-phenyl, 2-NH2-phenyl, 4-CF3-phenyl, 3-CF3-phenyl, 2-CF3-phenyl, 2,3-di-Me-phenyl, 2,4-di-Me-phenyl, 2,5-di-Me-phenyl, 2,6-di-Me-phenyl, 4-morpholino-phenyl, 3-morpholino-phenyl, 2-morpholino-phenyl, 4-CN-2-morpholino-phenyl, 4-CH3-2-morpholino-phenyl or 4-OH-2-morpholino-phenyl.

[0291] In any of the embodiments described herein, C6-C 10 Aryl is naphthyl. In embodiments, naphthyl is unsubstituted naphthyl. In embodiments, naphthyl is unsubstituted naphthyl (e.g., phenyl comprising 1, 2, 3, 4, or 5 substituents, including exemplary substituents described herein). In embodiments, naphthyl is attached to the molecule at the C1 position (1-naphthyl). In embodiments, naphthyl is attached to the molecule at the C2 position (2-naphthyl). In embodiments, naphthyl is attached to the molecule at the C3 position (3-naphthyl). In embodiments, naphthyl is attached to the molecule at the C4 position (4-naphthyl). In embodiments, naphthyl is attached to the molecule at the C5 position (5-naphthyl). In embodiments, naphthyl is attached to the molecule at the C6 position (6-naphthyl). In embodiments, naphthyl is attached to the molecule at the C7 position (7-naphthyl). In embodiments, naphthyl is attached to the molecule at the C8 position (8-naphthyl). In an embodiment, the substituted naphthyl comprises 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of naphthyl are described herein.

[0292] In embodiments of any formula described herein, the 5 to 10 membered heteroaryl is imidazolyl. In embodiments, the imidazolyl is unsubstituted imidazolyl. In embodiments, the imidazolyl is unsubstituted imidazolyl (e.g., an imidazolyl comprising 1, 2, or 3 substituents, the substituents including the exemplary substituents described herein). In embodiments, the imidazolyl is an N-attached imidazolyl and is attached to the molecule via the N1 position (1-imidazolyl) of the imidazolyl. In embodiments, the imidazolyl is a C-attached imidazolyl. In embodiments, the imidazolyl is attached to the molecule via the C2 position (2-imidazolyl) of the imidazolyl. In embodiments, the imidazolyl is attached to the molecule via the C4 position (4-imidazolyl) of the imidazolyl. In embodiments, the imidazolyl is attached to the molecule via the C5 position (5-imidazolyl) of the imidazolyl. In an embodiment, the substituted imidazolyl comprises 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. In an embodiment, the substituted imidazolyl is N-methylimidazolyl. Other exemplary embodiments of imidazolyl are described herein.

[0293] In embodiments of any formula described herein, the 5 to 10 membered heteroaryl is pyrrolyl. In embodiments, the pyrrolyl is an unsubstituted pyrrolyl. In embodiments, the pyrrolyl is an N-connected pyrrolyl and is attached to the molecule via the N1 position of the pyrrolyl (1-pyrrolyl). In embodiments, the pyrrolyl is a C-connected pyrrolyl. In embodiments, the pyrrolyl is attached to the molecule via the C2 position of the pyrrolyl (2-pyrrolyl). In embodiments, the pyrrolyl is attached to the molecule via the C3 position of the pyrrolyl (3-pyrrolyl). In embodiments, the pyrrolyl is attached to the molecule via the C4 position of the pyrrolyl (4-pyrrolyl). In embodiments, the pyrrolyl is attached to the molecule via the C5 position of the pyrrolyl (5-pyrrolyl). In embodiments, the pyrrolyl is an unsubstituted pyrrolyl (e.g., a pyrrolyl comprising 1, 2, or 3 substituents, including exemplary substituents described herein). In an embodiment, the substituted pyrrolyl group comprises 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of pyrrolyl are described herein.

[0294] In embodiments of any formula described herein, 5 to 10 yuan heteroaryl is oxazolyl. In embodiments, oxazolyl is unsubstituted oxazolyl. In embodiments, oxazolyl is attached to the molecule via the C2 position (2-oxazolyl) of oxazolyl. In embodiments, oxazolyl is attached to the molecule via the C3 position (3-oxazolyl) of oxazolyl. In embodiments, oxazolyl is attached to the molecule via the C4 position (4-oxazolyl) of oxazolyl. In embodiments, oxazolyl is unsubstituted oxazolyl (e.g., oxazolyl comprising 1 or 2 substituents, the substituents comprising the exemplary substituents described herein). In embodiments, substituted oxazolyl comprises 1 or 2 substituents selected from the group consisting of: OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of imidazoles are described herein.

[0295] In embodiments of any formula described herein, the 5 to 10 membered heteroaryl is tetrazolyl. In embodiments, the tetrazolyl is unsubstituted tetrazolyl. In embodiments, the tetrazolyl is unsubstituted tetrazolyl (e.g., N-substituted tetrazolyl including the exemplary substituents described herein). Other exemplary embodiments of tetrazolyl are described herein.

[0296] In embodiments of any formula described herein, the 5 to 10 membered heteroaryl is pyridyl. In embodiments, the pyridyl is unsubstituted pyridyl. In embodiments, the pyridyl is attached to the molecule via the C2 position (2-pyridyl). In embodiments, the pyridyl is attached to the molecule via the C3 position (3-pyridyl). In embodiments, the pyridyl is attached to the molecule via the C4 position (4-pyridyl). In embodiments, the pyridyl is attached to the molecule via the C2 position (5-pyridyl). In embodiments, the pyridyl is attached to the molecule via the C2 position (a-6-pyridyl). In embodiments, the pyridyl is unsubstituted pyridyl (e.g., a pyridyl comprising 1, 2, 3, or 4 substituents, including exemplary substituents described herein). In an embodiment, the substituted pyridyl group comprises 1, 2 or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. Other exemplary embodiments of pyridyl groups are described herein.

[0297] In embodiments of any formula described herein, the 5- to 10-membered heteroaryl is pyrazinyl. In embodiments, the pyrazinyl is unsubstituted pyrazinyl. In embodiments, the pyrazinyl is 2-pyrazinyl. In embodiments, the pyrazinyl is 3-pyrazinyl. In embodiments, the pyrazinyl is 5-pyrazinyl. In embodiments, the pyrazinyl is 6-pyrazinyl. In embodiments, the pyrazinyl is unsubstituted pyrazinyl (e.g., pyrazinyl comprising 1, 2, 3, or 4 substituents, including the exemplary substituents described herein). In embodiments, the substituted pyrazinyl comprises 1, 2, or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3, and CO2NH2. Other exemplary embodiments of pyrazinyl are described herein.

[0298] In embodiments of any formula described herein, the 5 to 10 membered heteroaryl is indolyl. In embodiments, the indolyl is an unsubstituted indolyl. In embodiments, the indolyl is an N-attached indolyl and is attached to the molecule via the N1 position of the indolyl (1-indolyl). In embodiments, the indolyl is a C-attached indolyl. In embodiments, the indolyl is attached to the molecule via the C2 position (2-indolyl). In embodiments, the indolyl is attached to the molecule via the C3 position (3-indolyl). In embodiments, the indolyl is attached to the molecule via the C4 position (4-indolyl). In embodiments, the indolyl is attached to the molecule via the C5 position (5-indolyl). In embodiments, the indolyl is attached to the molecule via the C6 position (6-indolyl). In embodiments, the indolyl is attached to the molecule via the C7 position (7-indolyl). In an embodiment, indolyl is an unsubstituted indolyl (e.g., an indolyl comprising 1, 2, 3, or 4 substituents, including the exemplary substituents described herein). In an embodiment, the substituted indolyl comprises 1, 2, or 3 substituents selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3, and CO2NH2. Other exemplary embodiments of indolyl are described herein.

[0299] In embodiments of any of the formulae described herein, the substituents are selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio halogen, cyano, carbamoyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five to six membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen. In an embodiment, the substituent itself is unsubstituted. In an embodiment, the substituent is selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0300] In embodiments of any of the formulas described herein, the C5 carbon of the 2-dihydrofuranone core has the (R)-configuration.

[0301] In embodiments of any of the formulas described herein, the C5 carbon of the 2-dihydrofuranone core has the (S)-configuration.

[0302] In embodiments of any of the formulae described herein, R A or R AA The substituted carbon has the (R)-configuration.

[0303] In embodiments of any of the formulae described herein, R A or R AA The carbon of has the (S)-configuration.

[0304] Compounds of formula (I*) and (I**)

[0305] Described herein are compounds of Formula (I*) and exemplary embodiments of Formula (I*).

[0306] The exemplary formulae and compounds described herein may also encompass hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

[0307] In one aspect, the invention features a compound having a structure according to formula (I*)

[0308]

[0309] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0310] R 1N Selected from the group consisting of: imidazole, oxazole, isoxazole in

[0311] Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0312] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0313] Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0314] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0315] R 8jSelected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0316] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0317] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0318] Each R AA are independently C1-C7 straight chain alkyl groups;

[0319] Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN;

[0320] a is 0, 1, or 2;

[0321] aa is 0, 1, or 2; and

[0322] y 1 Is 0, 1, or 2.

[0323] In another aspect, the invention features a compound having a structure according to formula (I*-N)

[0324]

[0325] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0326] R 1N-N Selected from the group consisting of: C6-C 10 Heteroaryl, five- to ten-membered heteroaryl, in

[0327] Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0328] R 5Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0329] Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0330] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0331] R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0332] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0333] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0334] Each R AA are independently C1-C7 straight chain alkyl groups;

[0335] Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN;

[0336] a is 0, 1, or 2;

[0337] aa is 0, 1 or 2;

[0338] y 1 is 0, 1, or 2; and

[0339] When R 5 When it is an unsubstituted C1-C7 alkyl group or an unsubstituted C3-C7 cycloalkyl group, a is 1 or 2.

[0340] In an embodiment, R 5 When it is an unsubstituted C1-C7 alkyl group or an unsubstituted C3-C7 cycloalkyl group, a is 1 or 2.

[0341] In an embodiment, the compound according to formula (I*) has the structure of:

[0342] Where R 1N , R AA , R 2a , aa and a are consistent with any aspect or embodiment described herein.

[0343] In an embodiment, the compound according to formula (I*) has the structure of:

[0344] Where R 1N , R AA , R 2a , aa and a are consistent with any aspect or embodiment described herein.

[0345] In an embodiment, the compound according to formula (I*-N) has a structure according to the following formula:

[0346] Where R 1N-N , R AA , R 2a , aa and a are consistent with any aspect or embodiment described herein.

[0347] In an embodiment, the compound according to formula (I*-N) has a structure according to the following formula:

[0348] Where R 1N-N , R AA , R 2a, aa and a are consistent with any aspect or embodiment described herein.

[0349] In an embodiment, each R AA is independently a C1-C7 straight chain alkyl. AA are independently methyl.

[0350] In an embodiment, a is 0. In an embodiment, a is 1. In an embodiment, a is 2. In an embodiment, a is not 0. In an embodiment, a does not include 0. In an embodiment, a is 0 or 1. In an embodiment, a is 1 or 2.

[0351] In an embodiment, each R 2a is independently halogen. In an embodiment, each R 2a is independently F. In an embodiment, each R 2a are independently Cl.

[0352] In an embodiment, aa is 0. In an embodiment, aa is 1. In an embodiment, aa is 2. In an embodiment, aa is 1 or 2.

[0353] In an embodiment, R 1N Selected from the group consisting of: imidazole, oxazole, isoxazole, in

[0354] Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0355] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0356] Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0357] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0358] R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0359] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0360] R 9 is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; and

[0361] y 1 Is 0, 1, or 2.

[0362] In an embodiment, R 1N-N Selected from the group consisting of: C6-C 10 Heteroaryl, five- to ten-membered heteroaryl, in

[0363] Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0364] R 5Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0365] Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0366] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0367] R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0368] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0369] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0370] R 11 is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; and

[0371] y 1 Is 0, 1, or 2.

[0372] In an embodiment, R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and In an embodiment, R 5 Unsubstituted C1-C7 alkyl is excluded. In an embodiment, R 5 Unsubstituted C3-C7 cycloalkyl groups are excluded.

[0373] In an embodiment, R 1N for In an embodiment, R 1N-N for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0374] In an embodiment, R 1N for In an embodiment, R 1N-N for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0375] In an embodiment, R 1N-N for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0376] In an embodiment, y 1 is 0 and R 1COR 5 In an embodiment, R 5 is pyridinyl. 5 In one embodiment, R 5 is C1-C7 alkyl. In an embodiment, R 5 is a C3-C7 cycloalkyl group. 5 is a C1-C7 haloalkyl group. 5 is a C3-C7 cyclohaloalkyl. 5 is a C1-C7 fluoroalkyl group. 5 It is a C3–C7 cyclofluoroalkyl group.

[0377] In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0378] In an embodiment, R 4a is H. In an embodiment, R 4b is H. In an embodiment, R 4a and R 4b All are H. In the embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0379] In an embodiment, R 5 is pyridinyl. 5 In one embodiment, R 5 is C1-C7 alkyl. In an embodiment, R 5 is a C3-C7 cycloalkyl group. 5 is C1-C7 haloalkyl. In an embodiment, R 5 is a C3-C7 cyclohaloalkyl. 5 is a C1-C7 fluoroalkyl group. 5 is a C3-C7 cyclofluoroalkyl group. 5 is an unsubstituted C1-C7 alkyl. In an embodiment, R 5 is an unsubstituted C1-C7 alkyl group (e.g., comprising an amino substituent such as -NH2, -NHCH3, or -N(CH3)2). 5 In an embodiment, R 5 is unsubstituted phenyl. In an embodiment, R 5 is a substituted phenyl.5 NR 8a R 8b In an embodiment, R 5 For SO2R 8c In an embodiment, R 5 NR 8d S02R 8e In an embodiment, R 5 NR 8i COOR 8j In an embodiment, R 5 For NHCONR 8f In an embodiment, R 5 NR 8g COR 8h In an embodiment, R 5 It is not an unsubstituted C1-C7 alkyl group.

[0380] In an embodiment, R 11 is hydrogen. In an embodiment, R 11 is C1-C7 alkyl (eg, methyl). 11 It is a C3-C7 cycloalkyl group.

[0381] In an embodiment, R 1N or R 1N-N for

[0382] in,

[0383] R 4a ,R 4b and 1 Complying with any aspect or embodiment described herein;

[0384] Z a is CH2 or O;

[0385] When Z a When it is CH2, p 1 +p 2 is 1, 2, 3, or 4; and

[0386] When Z a When p is O, 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 Both are not 0.

[0387] In an embodiment, R 4a and R 4b Together with the atoms to which they are attached, they form a carbocyclic ring containing 3 to 7 atoms. 4a and R4b Together with the atoms to which they are bound, they form oxygen-containing rings containing 3 to 7 atoms.

[0388] In an embodiment, R 1N or R 1N-N for in

[0389] Z b is CH2 or O;

[0390] When Z b When it is CH2, p 1 +p 2 is 1, 2, 3, or 4;

[0391] When Z b O,p 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 All are not 0;

[0392] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0393] Each R 8a ,R 8b ,R 8d ,R 8g ,R 8i and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0394] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0395] R8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl;

[0396] Each R 8c ,R 8e ,R 8f and R 8h It is a C1-C7 alkyl group or a C3-C7 cycloalkyl group.

[0397] In an embodiment, R 1N or R 1N-N for

[0398] in,

[0399] R 4a ,R 4b and 1 Complying with any aspect or embodiment described herein;

[0400] R 10a and R 10b independently selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, SO2R 8e 、COOR 8j ,CONR 8f and COR 8h ;and

[0401] R 10a and R 10b At least one of is selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl and C3-C7 cycloalkyl;

[0402] Each R 8e , R 8f and R 8h Selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl.

[0403] In an embodiment, R 1N-N For urea groups (e.g. ).

[0404] In an embodiment, R 1N or R 1N-N is a carbamate group (e.g., ). In an embodiment, R 1N is an aminoacyl group (e.g. ). In an embodiment, R 1N is an alkyl acyl group (e.g., ). In an embodiment, R 1N or R 1N-N In an embodiment, R 1N is a heteroaryl group (for example, ). In an embodiment, R 1N is a heteroaryl group containing an acyl group (e.g. ).

[0405] In an embodiment, R 1N or R 1N-N for Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 Selected from the group consisting of hydrogen, C1-C7 alkyl and C3-C7 cycloalkyl.

[0406] In an embodiment, R 1N or R 1N-N for Where uu is 1 or 2.

[0407] In an embodiment, R 1N or R 1N-N for

[0408] In an embodiment, R 1N or R 1N-N for Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0409] In an embodiment, R 1N or R 1N-N for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0410] In an embodiment, R 1N or R 1N-N for

[0411] In an embodiment, R 1N or R 1N-N for Each R 8a and R 8b and are independently H or unsubstituted C1-C7 alkyl.

[0412] In an embodiment, R 1N or R 1N-N for Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e It is an unsubstituted C1-C7 alkyl group.

[0413] In an embodiment, R 1N or R 1N-N for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0414] In an embodiment, R 1N or R 1N-N for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0415] In an embodiment, R 1N or R 1N-N for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0416] In an embodiment, R 1N or R 1N-N for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0417] In an embodiment, R 1N or R 1N-N for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0418] In an embodiment, R 1N or R 1N-N for Where R8h It is an unsubstituted C1-C7 alkyl group.

[0419] In an embodiment, R 1N or R 1N-N for In an embodiment, R 1N or R 1N-N for In an embodiment, R 1N or R 1N-N for

[0420] In an embodiment, R 1N or R 1N-N for Each R 8a ,R 8b and R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h It is an unsubstituted C1-C7 alkyl group.

[0421] In an embodiment, R 1N or R 1N-N for Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0422] In an embodiment, R 1N or R 1N-N for

[0423] In an embodiment, R 1N or R 1N-N for

[0424] In an embodiment, R 1N or R 1N-N for Each R 8a and R 8b and are independently H or unsubstituted C1-C7 alkyl.

[0425] In an embodiment, R 1N or R 1N-N for Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h and are independently unsubstituted C1-C7 alkyl.

[0426] In an embodiment, R 1N or R 1N-N for

[0427] In an embodiment, R 1N or R 1N-N for

[0428] In an embodiment, R 1N or R 1N-N for

[0429] In an embodiment, the compound according to formula (I*) or (I*-N) has the structure of:

[0430] Each R 5 ,R 4a ,R 4b ,R 2a ,R AA ,y 1 , aa and a are consistent with any aspect or embodiment described herein.

[0431] In an embodiment, the compound according to formula (I*) or (I*-N) has the structure of:

[0432] Each R 5 ,R 4a ,R 4b ,R 2a ,R AA ,y 1 , aa and a are consistent with any aspect or embodiment described herein.

[0433] In an embodiment, the compound according to formula (I*-N) has the structure of:

[0434] Each R 5 ,R 11 ,R 4a ,R 4b ,R 2a ,R AA ,y 1 , aa and a are consistent with any aspect or embodiment described herein.

[0435] In an embodiment, the compound according to formula (I*-1), (I*-2) or (I*-3) has one of the following structures:

[0437]

[0438]

[0439] Each R 5 ,R 11 ,R 4a ,R 4b ,R 2a ,R AA ,y 1 , aa and a are consistent with any aspect or embodiment described herein.

[0440] In another aspect, the invention features a compound having a structure according to formula (I**)

[0441]

[0442] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0443] Each R aa and R bb selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 branched alkyl;

[0444] Each R AA are independently C1-C7 straight chain alkyl groups;

[0445] Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN;

[0446] a' is 1 or 2; and

[0447] aa is 0, 1 or 2.

[0448] In an embodiment, the compound according to formula (I**) has the structure of:

[0449] Where R aa , R bb , R AA ,R 2a , aa and a' are consistent with any aspect or embodiment described herein.

[0450] In an embodiment, the compound according to formula (I**) has the structure of:

[0451] Where R aa , R bb , R AA,R 2a , aa and a' are consistent with any aspect or embodiment described herein.

[0452] In an embodiment, each R AA is independently a C1-C7 straight chain alkyl. AA are independently methyl.

[0453] In an embodiment, a' is 1. In an embodiment, a' is 2. In an embodiment, a' is 1 or 2.

[0454] In an embodiment, each R 2a is independently halogen. In an embodiment, each R 2a is independently F. In an embodiment, each R 2a are independently Cl.

[0455] In an embodiment, aa is 0. In an embodiment, aa is 1. In an embodiment, aa is 2. In an embodiment, aa is 1 or 2.

[0456] In an embodiment, R aa is a C1-C7 straight chain alkyl group. aa is a C3-C7 branched alkyl group. aa In the embodiment, R bb is a C1-C7 straight chain alkyl group. bb is a C3-C7 branched alkyl group. bb In the embodiment, R aa and R bb Each is an ethyl group.

[0457] Compounds of formula (I)

[0458] In one aspect, the invention features a compound having a structure according to formula (I)

[0459]

[0460] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0461] Each R a and R b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 branched alkyl; or R a and R b Together with the atoms to which they are attached, they form a carbocyclic ring having 5 to 7 ring atoms, optionally containing a double bond; or R a and Rb Together with the atoms to which they are attached, they form a ring having 6-8 ring atoms, the ring comprising a member selected from O, S, SO, SO2 and NR 1 part of;

[0462] A is an N-linked five to twelve membered nitrogen-containing heterocyclic group, wherein the nitrogen-containing heterocyclic group is bicyclic or polycyclic and optionally contains other heteroatoms selected from O, N and S, and wherein the non-aromatic nitrogen-containing heterocyclic group further contains a group R 2 ;

[0463] R 1 is H, C1-C7 alkyl, C3-C7 cycloalkyl, phenyl, benzyl, a five-membered to six-membered heteroaryl ring, a polar acyl group or a polar sulfonyl group;

[0464] R 2 is selected from the group consisting of a 6- to 10-membered aryl group, a 5- to 10-membered nitrogen-containing heteroaryl group, and

[0465] R 3 is a 6- to 10-membered aryl group or a 5- to 10-membered nitrogen-containing heteroaryl group;

[0466] m is 1, 2 or 3; and

[0467] n is 1, 2, 3 or 4.

[0468] In an embodiment, when A is 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, octahydropyrrolo[3,4-c]pyrrol-1-yl or 2,6-diazaspiro[3.3]hept-1-yl, then R a and R b cannot be all methyl, all ethyl, or all phenyl, and R a and R b Nor can they combine to form unsubstituted C3-C6 cycloalkyl groups.

[0469] In an embodiment, A is not 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, octahydropyrrolo[3,4-c]pyrrol-1-yl, or 2,6-diazaspiro[3.3]hept-1-yl. In an embodiment, A does not include 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, octahydropyrrolo[3,4-c]pyrrol-1-yl, or 2,6-diazaspiro[3.3]hept-1-yl.

[0470] In an embodiment, R a and R bTogether with the atoms to which they are attached, they form a ring having 6 to 8 ring atoms, wherein one of the ring atoms is selected from the group consisting of: O, S, SO, SO2 and NR 1 .

[0471] In an embodiment, the compound according to formula (I) has the structure of:

[0472] Where R a ,R b , A and n are consistent with any aspect or embodiment described herein.

[0473] In an embodiment, the compound according to formula (I) has the structure of:

[0474] Where R a ,R b , A and n are consistent with any aspect or embodiment described herein.

[0475] In an embodiment, each R a and R b It is methyl.

[0476] In an embodiment, each R a and R b It is ethyl.

[0477] In an embodiment, R a and R b Combine to form unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In an embodiment, R a and R b Combined to form an unsubstituted cyclopropyl group. In an embodiment, R a and R b Combined to form an unsubstituted cyclobutyl group. In an embodiment, R a and R b Combined to form an unsubstituted cyclopentyl. In an embodiment, R a and R b Combine to form an unsubstituted cyclohexyl group.

[0478] In an embodiment, R a and R b Together with the atoms to which they are attached, they form a ring having 6 to 8 ring atoms, the ring containing 1 part.

[0479] In an embodiment, R a and R b Combination to form The group.

[0480] In an embodiment, the compound according to formula (I) has the structure of:

[0481] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0482] In an embodiment, the compound according to formula (I) has the structure of:

[0483] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0484] In an embodiment, the compound according to formula (I) has the structure of:

[0485] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0486] In an embodiment, the compound according to formula (I) has the structure of:

[0487] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0488] In an embodiment, the compound according to formula (I) has the structure of:

[0489] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0490] In an embodiment, the compound according to formula (I) has the structure of:

[0491] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0492] In an embodiment, the compound according to formula (I) has the structure of:

[0493] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0494] In an embodiment, the compound according to formula (I) has the structure of:

[0495] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0496] In an embodiment, the compound according to formula (I) has the structure of:

[0497] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0498] In an embodiment, the compound according to formula (I) has the structure of:

[0499] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0500] In an embodiment, the compound according to formula (I) has the structure of:

[0501] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0502] In an embodiment, the compound according to formula (I) has the structure of:

[0503] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0504] In an embodiment, the compound according to formula (I) has the structure of:

[0505] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0506] In an embodiment, the compound according to formula (I) has the structure of:

[0507] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0508] In an embodiment, the compound according to formula (I) has the structure of:

[0509] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0510] In an embodiment, the compound according to formula (I) has the structure of:

[0511] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0512] In an embodiment, the compound according to formula (I) has the structure of:

[0513] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0514] In an embodiment, the compound according to formula (I) has the structure of:

[0515] In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3.

[0516] In an embodiment, A is selected from the group consisting of:

[0517]

[0518]

[0519] in

[0520] R 2 Selected from the group consisting of phenyl, naphthyl, pyridyl, indolyl and

[0521] R 3 selected from the group consisting of phenyl, naphthyl, pyridyl and indolyl;

[0522] R A Selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl , carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; and

[0523] a is 0, 1 or 2.

[0524] In an embodiment, a is 0.

[0525] In an embodiment, a is 1.

[0526] In an embodiment, a is 2.

[0527] In an embodiment, A is selected from the group consisting of:

[0528]

[0529]

[0530] In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is In an embodiment, A is

[0531] In an embodiment, A is

[0532] In an embodiment, A is

[0533] In an embodiment of formula (I), A is selected from the group consisting of:

[0534]

[0535] In an embodiment, a is 0.

[0536] In an embodiment, a is 1.

[0537] In an embodiment, a is 2.

[0538] In an embodiment, A is

[0539] In an embodiment, A is

[0540] In an embodiment, A is

[0541] In an embodiment, A is

[0542] In an embodiment, R 2 In an embodiment, R 2 is unsubstituted phenyl. In an embodiment, R 2 is phenyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 2 is fluorophenyl (e.g., 2-, 3-, or 4-fluorophenyl), difluorophenyl, chlorophenyl (e.g., 2-, 3-, or 4-chlorophenyl), dichlorophenyl, chlorofluorophenyl. 2 is phenyl substituted by 1, 2 or 3 groups (e.g., one or two groups) selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0543] In an embodiment, R 2 In an embodiment, R 2 is unsubstituted naphthyl. In an embodiment, R 2 is phenyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 2 is naphthyl substituted by 1, 2 or 3 groups (e.g., one or two groups): OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0544] In an embodiment, R 2 is pyridinyl. 2 is 2-pyridyl. In an embodiment, R 2 is 3-pyridyl. 2 is 4-pyridyl. In an embodiment, R 2 is unsubstituted pyridinyl. In an embodiment, R 2 is pyridinyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 2 is pyridinyl substituted by 1, 2 or 3 groups (e.g., one or two groups): OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0545] In an embodiment, R 2 In an embodiment, R 2 is unsubstituted indolyl. In an embodiment, R 2 is indolyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 2 is indolyl substituted by 1, 2 or 3 groups (e.g., one or two groups): OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0546] In an embodiment, R 2 is phenyl, naphthyl, pyridyl or

[0547] In an embodiment, R 2 for Where aa is 0, 1, 2, or 3, and each R 2a is independently any substituent described herein. In an embodiment, each R 2a is independently selected from OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. In an embodiment, each R 2aindependently selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, aminomethyl Acyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.

[0548] In an embodiment, R 2 for In an embodiment, m is 1. In an embodiment, m is 2. In an embodiment, m is 3.

[0549] In an embodiment, R 3 In an embodiment, R 3 is unsubstituted phenyl. In an embodiment, R 3 is phenyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 3 is fluorophenyl (e.g., 2-, 3-, or 4-fluorophenyl), difluorophenyl, chlorophenyl (e.g., 2-, 3-, or 4-chlorophenyl), dichlorophenyl, chlorofluorophenyl. 3 is phenyl substituted by 1, 2 or 3 groups (e.g., one or two groups) selected from the group consisting of OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0550] In an embodiment, R 3 In an embodiment, R 3 is unsubstituted naphthyl. In an embodiment, R 3 is phenyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 3is naphthyl substituted by 1, 2 or 3 groups (e.g., one or two groups): OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0551] In an embodiment, R 3 is pyridinyl. 3 is 2-pyridyl. In an embodiment, R 3 is 3-pyridyl. 3 is 4-pyridyl. In an embodiment, R 3 is unsubstituted pyridinyl. In an embodiment, R 3 is pyridinyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 3 is pyridinyl substituted by 1, 2 or 3 groups (e.g., one or two groups): OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0552] In an embodiment, R 3 In an embodiment, R 3 is unsubstituted indolyl. In an embodiment, R 3 is indolyl, which contains at least one halogen substituent (e.g., at least one substituent that is chlorine or fluorine). 3 is indolyl substituted by 1, 2 or 3 groups (e.g., one or two groups): OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2.

[0553] In an embodiment, R 3 It is phenyl, naphthyl or pyridyl.

[0554] In an embodiment, R 3 for Where aa is 0, 1, 2, or 3, and each R 3a is independently any substituent described herein. In an embodiment, each R 3a is independently selected from OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. In an embodiment, each R 3aindependently selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, aminomethyl Acyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.

[0555] In a specific embodiment, A is Where R 2a Selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl , carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; R ASelected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl, carboxyl, C1-C7 straight chain alkyl, C3-C7 branched chain ... -C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and a five- to six-membered heterocyclic group, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; and a is independently 0, 1 or 2.

[0556] In an embodiment, R 1 C6-C 10 Aryl.

[0557] In an embodiment, R 1 is a five-membered to six-membered heteroaryl ring. 1 is imidazolyl (eg, unsubstituted imidazolyl or N-methylimidazolyl). 1 is oxazolyl (eg, unsubstituted oxazolyl). In an embodiment, R 1 is isoxazolyl (eg, unsubstituted oxazolyl).

[0558] In an embodiment, R 1 for Where X is O, NH or NCH3, aa1 is 0, 1 or 2 and R 1aSelected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl The invention also includes an alkyl group, a carboxyl group, a C1-C7 alkoxycarbonyl group, a sulfo group, a halogen group, a C1-C7 alkylthio group, an arylthio group, a C1-C7 alkylsulfinyl group, an arylsulfinyl group, a C1-C7 alkylsulfonyl group, an arylsulfonyl group, an amino group, a C1-C7 acylamino group, a mono- or di-C1-C7 alkylamino group, a C3-C7 cycloalkylamino group, an arylamino group, a C2-C7 acyl group, an arylcarbonyl group and a five- to six-membered heterocyclic group, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.

[0559] In an embodiment, R 1 Selected from the group consisting of: In an embodiment, R 1 for

[0560] In an embodiment, R 1 For polar acyl groups (e.g., substructure

[0561] ). In an embodiment, R 1 is an acyl moiety comprising a C1-C7 alkyl group, a C3-C7 cycloalkyl group (e.g., a cyclopropyl group, a cyclobutyl group, a cyclopentyl group or a cyclohexyl group), a C1-C7 haloalkyl group, a C3-C7 cyclohaloalkyl group (e.g., a cyclohalopropyl group, a cyclohalobutyl group, a cyclohalopentyl group or a cyclohalohexyl group), a 4-6 membered oxygen-containing heterocyclic group (e.g., an oxetanyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group or an oxaziridine group) or a 4-6 membered nitrogen-containing heterocyclic group (e.g., an azetidinyl group, a pyrrolidinyl group or a piperidinyl group), wherein the group comprises a substituent , the substituent is an amino group (e.g., -NH2, a monoalkylamino group (e.g., -NHMe), or a dialkylamino group (e.g., -NMe2)), an acetylamino group (e.g., -NHCOMe or NMeCOMe), a carbamate group (e.g., -NHCO2Me or -NMeCO2Me), an alkylsulfonylamino group (e.g., -NHSO2Me or -NMeSO2Me), or a 5-10 membered nitrogen-containing heterocycle (e.g., tetrazolyl, imidazolyl, N-methylimidazolyl, pyridyl or pyridazinyl). In an embodiment, R 1is alkylacyl (e.g., -C(O)(C1-C7 alkyl) or -C(O)(C3-C7 cycloalkyl)). In an embodiment, R 1 Unsubstituted alkyl acyl (e.g., -C(O)(C1-C7 alkyl) or -C(O)(C3-C7 cycloalkyl)) is not included. In an embodiment, R 1 is a polar sulfonyl group (e.g., substructure As further described herein). In an embodiment, R 1 is an acyl moiety comprising a C1-C7 alkyl group, a C3-C7 cycloalkyl group (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), a C1-C7 haloalkyl group, a C3-C7 cyclohaloalkyl group (e.g., cyclohalopropyl, cyclohalobutyl, cyclohalopentyl or cyclohalohexyl), a 4-6 membered oxygen-containing heterocyclic group (e.g., oxetanyl, tetrahydrofuranyl, tetrahydropyranyl or oxazacyclopentanone) or a 4-6 membered nitrogen-containing heterocyclic group (e.g., azetidinyl, pyrrolidinyl or piperidinyl). wherein the group comprises a substituent which is an amino group (e.g., -NH2, a monoalkylamino group (e.g., -NHMe), or a dialkylamino group (e.g., -NMe2)), an acetylamino group (e.g., -NHCOMe or NMeCOMe), an alkylsulfonylamino group (e.g., -NHSO2Me or -NMeSO2Me), or a 5-10 membered nitrogen-containing heterocycle (e.g., a tetrazolyl group, an imidazolyl group, an N-methylimidazolyl group, a pyridyl group, or a pyridazinyl group).

[0562] In an embodiment, R 1 Selected from the group consisting of:

[0563]

[0564] Each R 4a ,R 4b ,R 4c ,R 6a ,R 6b and R 6c is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen; or R 6a and R 6b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0565] Each R 4d and R 6d Selected from the group consisting of phenyl, benzyl, pyridyl, -CH2(pyridyl), imidazole and -CH2(imidazole).

[0566] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0567] R 7 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NHCONR 8f ;

[0568] Each R 8a ,R 8b ,R 8d ,R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0569] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0570] R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10aryl and 5- to 10-membered heteroaryl; or

[0571] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0572] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0573] R 11 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0574] y 1 is 0, 1, or 2; and

[0575] y 2 Is 0, 1, or 2.

[0576] In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0577] In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0578] In an embodiment, R 4a is H. In an embodiment, R 4b is H. In an embodiment, R 4a and R 4b All are H. In the embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0579] In an embodiment, R 4a and R 4b Together with the atoms to which they are attached, they form a carbocyclic ring containing 3 to 7 atoms. 4a and R 4b Together with the atoms to which they are bound, they form oxygen-containing rings containing 3 to 7 atoms.

[0580] In an embodiment, R 4c is H. In an embodiment, R 4d In an embodiment, R4d is benzyl. In an embodiment, R 4d is pyridinyl. 4d is -CH2(pyridinyl). 4d is imidazole. In an embodiment, R 4d is -CH2(imidazole). In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0581] In an embodiment, R 6a is H. In an embodiment, R 6b is H. In an embodiment, R 6a and R 6b All are H. In the embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0582] In an embodiment, R 46 and R 6b Together with the atoms to which they are attached, they form a carbocyclic ring containing 3 to 7 atoms. 6a and R bb Together with the atoms to which they are bound, they form oxygen-containing rings containing 3 to 7 atoms.

[0583] In an embodiment, R 6c is H. In an embodiment, R 6d In an embodiment, R 6d is benzyl. In an embodiment, R 6d is pyridinyl. 6d is -CH2(pyridinyl). 6d is imidazole. In an embodiment, R 6d is -CH2(imidazole). In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0584] In an embodiment, R 5 is pyridinyl. 5 In one embodiment, R 5 is C1-C7 alkyl. In an embodiment, R 5 is a C3-C7 cycloalkyl group. 5is C1-C7 haloalkyl. In an embodiment, R 5 is a C3-C7 cyclohaloalkyl. 5 is a C1-C7 fluoroalkyl group. 5 is a C3-C7 cyclofluoroalkyl group. 5 is an unsubstituted C1-C7 alkyl. In an embodiment, R 5 is an unsubstituted C1-C7 alkyl group (e.g., comprising an amino substituent such as -NH2, -NHCH3, or -N(CH3)2). 5 In an embodiment, R 5 In an embodiment, R 5 is unsubstituted phenyl. In an embodiment, R 5 is a substituted phenyl. 5 NR 8a R 8b In an embodiment, R 5 For SO2R 8c In an embodiment, R 5 NR 8d S02R 8e In an embodiment, R 5 NR 8i COOR 8j In an embodiment, R 5 For NHCONR 8f In an embodiment, R 5 NR 8g COR 8h In an embodiment, R 5 It is not an unsubstituted C1-C7 alkyl group.

[0585] In an embodiment, R 7 is pyridinyl. 7 In one embodiment, R 7 is C1-C7 alkyl. In an embodiment, R 7 is a C3-C7 cycloalkyl group. 7 is C1-C7 haloalkyl. In an embodiment, R 7 is a C3-C7 cyclohaloalkyl. 7 is a C1-C7 fluoroalkyl group. 7 is a C3-C7 cyclofluoroalkyl group. 7 is an unsubstituted C1-C7 alkyl. In an embodiment, R 7 is a substituted C1-C7 alkyl.7 In an embodiment, R 7 In an embodiment, R 7 is unsubstituted phenyl. In an embodiment, R 7 is a substituted phenyl. 7 NR 8a R 8b In an embodiment, R 7 For SO2R 8c In an embodiment, R 7 NR 8d S02R 8e In an embodiment, R 7 For NHCONR 8f In an embodiment, R 7 It is not an unsubstituted C1-C7 alkyl group.

[0586] In an embodiment, R 4d Selected from the group consisting of:

[0587] Where R 4bb is H or CH3, a1 is 1 or 2, and each R 4aa is independently any substituent described herein. In an embodiment, each R 4aa is independently selected from OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. In an embodiment, each R 4aa independently selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, aminomethyl Acyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.

[0588] In an embodiment, R 6dSelected from the group consisting of:

[0589] Where R 6bb is H or CH3, a1 is 1 or 2, and each R 6aa is independently any substituent described herein. In an embodiment, each R 6aa is independently selected from OH, OCH3, NH2, CN, CH3, CF3, CH2CH3, isopropyl, F, Cl, Br, morpholino, CO2H, CO2CH3 and CO2NH2. In an embodiment, each R 6aa independently selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, aminomethyl Acyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.

[0590] In an embodiment, R 1 for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0591] In an embodiment, R 1 for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0592] In an embodiment, R 1 for In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0593] In an embodiment, R 1 for In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0594] In an embodiment, R 1 for In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0595] In an embodiment, R 1 for In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0596] In an embodiment, R 1 for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0597] In an embodiment, R 1 for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0598] In an embodiment, y 1 is 0 and R 1 COR 5 In an embodiment, R 5 is pyridinyl. 5 In one embodiment, R 5 is C1-C7 alkyl. In an embodiment, R 5 is a C3-C7 cycloalkyl group. 5 is a C1-C7 haloalkyl group. 5 is a C3-C7 cyclohaloalkyl. 5 is a C1-C7 fluoroalkyl group. 5 It is a C3–C7 cyclofluoroalkyl group.

[0599] In an embodiment, R 11 is hydrogen. In an embodiment, R 11 is C1-C7 alkyl (eg, methyl). 11 It is a C3-C7 cycloalkyl group.

[0600] In an embodiment, R 1 for

[0601] in,

[0602] R 4a ,R 4b and 1 Complying with any aspect or embodiment described herein;

[0603] Z a is CH2 or O;

[0604] When Z a When it is CH2, p 1 +p 2 is 1, 2, 3, or 4; and

[0605] When Z a When p is O, 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 Both are not 0.

[0606] In an embodiment, R 1 for in

[0607] Z b is CH2 or O;

[0608] When Z b When it is CH2, p 1 +p 2 is 1, 2, 3, or 4;

[0609] When Z b O,p 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 All are not 0;

[0610] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR8a R 8b 、SO2R 8c NR 8d S02R 8e NHCONR 8f NR 8g COR 8h and

[0611] Each R 8a ,R 8b ,R 8d ,R 8g and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0612] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0613] Each R 8c ,R 8e ,R 8f and R 8h It is a C1-C7 alkyl group or a C3-C7 cycloalkyl group.

[0614] In an embodiment, R 1 for in

[0615] Z c is CH2 or O;

[0616] When Z c For CH2, p 1 +p 2 is 1, 2, 3, or 4;

[0617] When Z c O,p 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 All are not 0;

[0618] R 7 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b、SO2R 8c NR 8d S02R 8e NHCONR 8f ;

[0619] Each R 8a ,R 8b ,R 8d ,R 8g and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0620] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0621] Each R 8c ,R 8e ,R 8f and R 8h It is a C1-C7 alkyl group or a C3-C7 cycloalkyl group.

[0622] In an embodiment, R 1 for

[0623] in,

[0624] R 10a and R 10b independently selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, SO2R 8e 、COOR 8j ,CONR 8f and COR 8h ;and

[0625] R 10a and R 10b At least one of is selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl and C3-C7 cycloalkyl;

[0626] Each R 8e ,R 8f and R 8h is selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl; and

[0627] R 8j Selected from the group consisting of: C1-C7 straight chain alkyl, C3-C7 branched alkyl, C3-C7 cycloalkyl, C6-C 10aryl and 5- to 10-membered heteroaryl.

[0628] In an embodiment, R 1 For COOR 5 , where R 5 C6-C 10 aryl or 5- to 10-membered heteroaryl.

[0629] In an embodiment, R 1 for Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 Selected from the group consisting of hydrogen, C1-C7 alkyl and C3-C7 cycloalkyl.

[0630] In an embodiment, R 1 for Where uu is 1 or 2.

[0631] In an embodiment, R 1 for Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0632] In an embodiment, R 1 for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0633] In an embodiment, R 1 for Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0634] In an embodiment, R 1 for Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl.

[0635] In an embodiment, R 1 for Where R 8dare independently H or unsubstituted C1-C7 alkyl, and R 8e It is an unsubstituted C1-C7 alkyl group.

[0636] In an embodiment, R 1 for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0637] In an embodiment, R 1 for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0638] In an embodiment, R 1 for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0639] In an embodiment, R 1 for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0640] In an embodiment, R 1 for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0641] In an embodiment, R 1 for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0642] In an embodiment, R 1 for

[0643] In an embodiment, R 1 for

[0644] In an embodiment, R 1 for

[0645] In an embodiment, R 1 for Each R 8a,R 8b and R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h It is an unsubstituted C1-C7 alkyl group.

[0646] In an embodiment, R 1 for

[0647] In an embodiment, R 1 for

[0648] In an embodiment, R 1 for

[0649] In an embodiment, R 1 for

[0650] In an embodiment, R 1 for

[0651] In an embodiment, R 1 for

[0652] In an embodiment, R 1 for

[0653] In an embodiment, R 1 for Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl.

[0654] In an embodiment, R 1 for Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h and independently unsubstituted C1-C7 alkyl.

[0655] In an embodiment, R 1 for

[0656] Compound of formula (II)

[0657] In one aspect, the invention features a compound having a structure according to formula (II)

[0658]

[0659] Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:

[0660]

[0661] R 2 is selected from the group consisting of a 6- to 10-membered aryl group, a 5- to 10-membered nitrogen-containing heteroaryl group, and

[0662] R 3 is a 6- to 10-membered aryl group or a 5- to 10-membered nitrogen-containing heteroaryl group;

[0663] m is 1, 2 or 3;

[0664] n is 1, 2, 3 or 4;

[0665] R 1’ Selected from the group consisting of: C6-C 10 Aryl, five-membered to six-membered heteroaryl ring,

[0666]

[0667] Each R 4a ,R 4b ,R 4c ,R 6a ,R 6b and R 6c selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0668] R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0669] R 6a and R 6b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen;

[0670] Each R 4d and R 6d Selected from the group consisting of phenyl, benzyl, pyridyl, -CH2(pyridyl), imidazole and -CH2(imidazole).

[0671] R 5Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and

[0672]

[0673] R 7 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NHCONR 8f ;

[0674] Each R 8a ,R 8b ,R 8d ,R 8g and R 8i is selected from the group consisting of hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or

[0675] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0676] Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl;

[0677] R 8jSelected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or

[0678] When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms;

[0679] R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0680] R 11 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0681] R A Selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl alkyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups each containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen;

[0682] a is 0, 1, or 2;

[0683] y 1 is 0, 1, or 2; and

[0684] y 2 Is 0, 1, or 2.

[0685] In the embodiment, when A 2 for R 2 is phenyl, R 1’ for y 2 When is 0 and n is 2, then R 7It is not methyl, CH2SO2CH3, CH2CN, tetrahydropyranyl, phenyl, 4-substituted phenyl or 5- to 8-membered heteroaryl.

[0686] In an embodiment, the compound according to formula (II) has a structure according to formula (II′) or formula (II”).

[0687]

[0688] In the implementation scheme, A 2 for

[0689] In the implementation scheme, A 2 for

[0690] In the implementation scheme, A 2 for

[0691] In an embodiment, R A Selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl R is a 5- to 6-membered heterocyclic group, wherein each of the 5- to 6-membered heterocyclic groups contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen. A For unsubstituted C 1- -C7 alkyl. In an embodiment, R A It is methyl.

[0692] In an embodiment, a is 0. In an embodiment, a is 1. In an embodiment, a is 2. In an embodiment, a is not 0. In an embodiment, a does not include 0. In an embodiment, a is 0 or 1. In an embodiment, a is 1 or 2.

[0693] In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0694] In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0695] In an embodiment, R 4a is H. In an embodiment, R 4b is H. In an embodiment, R 4a and R 4b All are H. In the embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0696] In an embodiment, R 4a and R 4b Together with the atoms to which they are attached, they form a carbocyclic ring containing 3 to 7 atoms. 4a and R 4b Together with the atoms to which they are bound, they form oxygen-containing rings containing 3 to 7 atoms.

[0697] In an embodiment, R 4c is H. In an embodiment, R 4d In an embodiment, R 4d is benzyl. In an embodiment, R 4d is pyridinyl. 4d is -CH2(pyridinyl). 4d is imidazole. In an embodiment, R 4d is -CH2(imidazole). In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0698] In an embodiment, R 6a is H. In an embodiment, R 6b is H. In an embodiment, R 6a and R 6b All are H. In the embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0699] In an embodiment, R 6a and R 6b The atoms to which they are attached are taken together to form a carbon ring containing 3 to 7 atoms.6a and R 6b Together with the atoms to which they are bound, they form oxygen-containing rings containing 3 to 7 atoms.

[0700] In an embodiment, R 6c is H. In an embodiment, R 6d In an embodiment, R 6d In an embodiment, R 6d is pyridinyl. 6d is -CH2(pyridinyl). 6d is imidazole. In an embodiment, R 6d is -CH2(imidazole). In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0701] In an embodiment, R 5 is pyridinyl. 5 In one embodiment, R 5 is C1-C7 alkyl. In an embodiment, R 5 is a C3-C7 cycloalkyl group. 5 is C1-C7 haloalkyl. In an embodiment, R 5 is a C3-C7 cyclohaloalkyl. 5 is a C1-C7 fluoroalkyl group. 5 is a C3-C7 cyclofluoroalkyl group. 5 is an unsubstituted C1-C7 alkyl. In an embodiment, R 5 is an unsubstituted C1-C7 alkyl group (e.g., comprising an amino substituent such as -NH2, -NHCH3, or -N(CH3)2). 5 In an embodiment, R 5 In an embodiment, R 5 is unsubstituted phenyl. In an embodiment, R 5 is a substituted phenyl. 5 NR 8a R 8b In an embodiment, R 5 For SO2R 8c In an embodiment, R 5 NR 8d S02R 8e In an embodiment, R 5 NR 8iCOOR 8j In an embodiment, R 5 For NHCONR 8f In an embodiment, R 5 NR 8g COR 8h In an embodiment, R 5 It is not an unsubstituted C1-C7 alkyl group.

[0702] In an embodiment, R 7 is pyridinyl. 7 In one embodiment, R 7 is C1-C7 alkyl. In an embodiment, R 7 is a C3-C7 cycloalkyl group. 7 is a C1-C7 haloalkyl group. 7 is a C3-C7 cyclohaloalkyl. 7 is a C1-C7 fluoroalkyl group. 7 is a C3-C7 cyclofluoroalkyl group. 7 is an unsubstituted C1-C7 alkyl. In an embodiment, R 7 is a substituted C1-C7 alkyl. 7 In an embodiment, R 7 In an embodiment, R 7 is unsubstituted phenyl. In an embodiment, R 7 is a substituted phenyl. 7 NR 8a R 8b In an embodiment, R 7 For SO2R 8c In an embodiment, R 7 NR 8d S02R 8e In an embodiment, R 7 For NHCONR 8f In an embodiment, R 7 It is not an unsubstituted C1-C7 alkyl group.

[0703] In an embodiment, R 1’ is a five-membered to six-membered heteroaryl ring. 1’ is imidazolyl (eg, unsubstituted imidazolyl or N-methylimidazolyl). 1 is oxazolyl (eg, unsubstituted oxazolyl). In an embodiment, R 1 is isoxazolyl (eg, unsubstituted oxazolyl).

[0704] In an embodiment, R 1’ for Where X is O, NH or NCH3, aa1 is 0, 1 or 2 and R 1a Selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl The invention also includes an alkyl group, a carboxyl group, a C1-C7 alkoxycarbonyl group, a sulfo group, a halogen group, a C1-C7 alkylthio group, an arylthio group, a C1-C7 alkylsulfinyl group, an arylsulfinyl group, a C1-C7 alkylsulfonyl group, an arylsulfonyl group, an amino group, a C1-C7 acylamino group, a mono- or di-C1-C7 alkylamino group, a C3-C7 cycloalkylamino group, an arylamino group, a C2-C7 acyl group, an arylcarbonyl group and a five- to six-membered heterocyclic group, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen.

[0705] In an embodiment, R 1’ Selected from the group consisting of: In an embodiment, R 1 for

[0706] In an embodiment, R 1’ for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0707] In an embodiment, R 1’ for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0708] In an embodiment, R 1’ for In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0709] In an embodiment, R 1’ for In an embodiment, y2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0710] In an embodiment, R 1’ for In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0711] In an embodiment, R 1’ for In an embodiment, y 2 is 0. In the implementation scheme, y 2 is 1. In the implementation scheme, y 2 is 2.

[0712] In an embodiment, R 1’ for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0713] In an embodiment, R 1’ for In an embodiment, y 1 is 0. In the implementation scheme, y 1 is 1. In the implementation scheme, y 1 is 2.

[0714] In an embodiment, y 1 is 0 and R 1’ COR 5 In an embodiment, R 5 is pyridinyl. 5 In one embodiment, R 5 is C1-C7 alkyl. In an embodiment, R 5 is a C3-C7 cycloalkyl group. 5 is a C1-C7 haloalkyl group. 5 is a C3-C7 cyclohaloalkyl. 5 is a C1-C7 fluoroalkyl group. 5 It is a C3–C7 cyclofluoroalkyl group.

[0715] In an embodiment, R 11 is hydrogen. In an embodiment, R 11is C1-C7 alkyl (eg, methyl). 11 It is a C3-C7 cycloalkyl group.

[0716] In an embodiment, R 1’ for

[0717] in,

[0718] R 4a ,R 4b and 1 Complying with any aspect or embodiment described herein;

[0719] Z a is CH2 or O;

[0720] When Z a When it is CH2, p 1 +p 2 is 1, 2, 3, or 4; and

[0721] When Z a When p is O, 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 Both are not 0.

[0722] In an embodiment, R 1’ for in

[0723] Z b is CH2 or O;

[0724] When Z b When it is CH2, p 1 +p 2 is 1, 2, 3, or 4;

[0725] When Z b O,p 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 All are not 0;

[0726] R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR8d S02R 8e NHCONR 8f NR 8g COR 8h and

[0727] Each R 8a ,R 8b ,R 8d ,R 8g and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0728] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0729] Each R 8c ,R 8e ,R 8f and R 8h It is a C1-C7 alkyl group or a C3-C7 cycloalkyl group.

[0730] In an embodiment, R 1’ for in

[0731] Z c is CH2 or O;

[0732] When Z c For CH2, p 1 +p 2 is 1, 2, 3, or 4;

[0733] When Z c O,p 1 +p 2 is 1, 2, 3 or 4; and p 1 and p 2 All are not 0;

[0734] R 7 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8eNHCONR 8f ;

[0735] Each R 8a ,R 8b ,R 8d ,R 8g and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl;

[0736] R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups;

[0737] Each R 8c ,R 8e ,R 8f and R 8h It is a C1-C7 alkyl group or a C3-C7 cycloalkyl group.

[0738] In an embodiment, R 1’ for

[0739] in,

[0740] R 10a and R 10b independently selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, SO2R 8e 、COOR 8j ,CONR 8f and COR 8h ;and

[0741] R 10a and R 10b At least one of is selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl and C3-C7 cycloalkyl;

[0742] Each R 8e ,R 8f and R 8h Selected from the group consisting of: H, C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl;

[0743] R 8j Selected from the group consisting of: C1-C7 straight chain alkyl, C3-C7 branched alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0744] In an embodiment, R1’ For COOR 5 , where R 5 C6-C 10 aryl or 5- to 10-membered heteroaryl.

[0745] In an embodiment, R 1’ for Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 Selected from the group consisting of hydrogen, C1-C7 alkyl and C3-C7 cycloalkyl.

[0746] In an embodiment, R 1’ for Where uu is 1 or 2.

[0747] In an embodiment, R 1’ for Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0748] In an embodiment, R 1’ for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0749] In an embodiment, R 1’ for Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0750] In an embodiment, R 1 for Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl.

[0751] In an embodiment, R 1’ for Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e It is an unsubstituted C1-C7 alkyl group.

[0752] In an embodiment, R 1’ for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0753] In an embodiment, R 1’ for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0754] In an embodiment, R 1’ for Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h It is an unsubstituted C1-C7 alkyl group.

[0755] In an embodiment, R 1’ for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0756] In an embodiment, R 1’ for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0757] In an embodiment, R 1’ for Where R 8h It is an unsubstituted C1-C7 alkyl group.

[0758] In an embodiment, R 1’ for

[0759] In an embodiment, R 1’ for

[0760] In an embodiment, R 1’ for

[0761] In an embodiment, R 1’ for Each R 8a ,R 8b and R 8gare independently H or unsubstituted C1-C7 alkyl, and R 8h It is an unsubstituted C1-C7 alkyl group.

[0762] In an embodiment, R 1’ for

[0763] In an embodiment, R 1’ for

[0764] In an embodiment, R 1’ for

[0765] In an embodiment, R 1’ for

[0766] In an embodiment, R 1’ for

[0767] In an embodiment, R 1’ for

[0768] In an embodiment, R 1’ for

[0769] In an embodiment, R 1’ for Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl.

[0770] In an embodiment, R 1’ for Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h and independently unsubstituted C1-C7 alkyl.

[0771] In an embodiment, R 1’ for

[0772] Compounds of formula (A)-(AAA)

[0773] Additional compounds of Formula (I), (I*), (I**), or (II) include compounds of any of Formula (A)-(AAA) as described herein, wherein any variable may conform to any aspect or embodiment as described herein.

[0774] The additional exemplary formulae and compounds described herein may also encompass hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.

[0775] For example, in any of the formulae described herein (e.g., any of Formulae (I), (I*), (II), and any of Formulae (A)-(AAA)), the C5 carbon of the 2-dihydrofuranone has the (R)-configuration.

[0776] Alternatively, in any of the formulae described herein (e.g., any of Formulae (I), (I*), (II), and any of Formulae (A)-(AAA)), the C5 carbon of the 2-dihydrofuranone has the (S)-configuration.

[0777] In an embodiment, provided herein is a compound having a structure according to Formula (A):

[0778] Where R a ,R b , A, n and aryl are consistent with any aspect or embodiment described herein.

[0779] In an embodiment, provided herein is a compound having a structure according to Formula (B):

[0780] Where Q 1 is 1 or 2, Q 2 is 1 or 2, and A and n are consistent with any aspect or embodiment described herein.

[0781] In an embodiment, provided herein is a compound having a structure according to Formula (C):

[0782] Where Q 1 is 1 or 2, Q 2 is 1 or 2, and A and n are consistent with any aspect or embodiment described herein.

[0783] In an embodiment, provided herein is a compound having a structure according to Formula (D):

[0784] Where Q 1 is 1 or 2, Q 2 is 1 or 2, and A and n are consistent with any aspect or embodiment described herein.

[0785] In an embodiment, provided herein is a compound having a structure according to Formula (E):

[0786] Where Q 1 is 1 or 2, Q 2 is 1 or 2, and A and n are consistent with any aspect or embodiment described herein.

[0787] In an embodiment, provided herein is a compound having a structure according to Formula (F):

[0788] Where Q 1 is 1 or 2, Q 2 is 1 or 2, and A and n are consistent with any aspect or embodiment described herein.

[0789] In an embodiment, provided herein is a compound having a structure according to Formula (G):

[0790] Where Q 1 is 1 or 2, Q 2 is 1 or 2, and A and n are consistent with any aspect or embodiment described herein.

[0791] In an embodiment, provided herein is a compound having a structure according to Formula (H):

[0792] Where Q 1 is 1 or 2, Q 2 is 1 or 2, and R 1 , A and n are consistent with any aspect or embodiment described herein.

[0793] In specific embodiments, provided herein are compounds having a structure according to Formula (J):

[0794] Each R a and R b selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 branched alkyl;

[0795] R 2 is selected from the group consisting of phenyl, naphthyl, pyridyl, indolyl; and

[0796] R 3 Selected from the group consisting of phenyl, naphthyl, pyridyl and indolyl.

[0797] In specific embodiments, provided herein are compounds having a structure according to Formula (K):

[0798] in

[0799] R 2 is selected from the group consisting of phenyl, naphthyl, pyridyl, indolyl; and

[0800] R 3 Selected from the group consisting of phenyl, naphthyl, pyridyl and indolyl.

[0801] In embodiments, provided herein are A compound wherein L A is any group for A described herein. In an embodiment, L A Selected from the group consisting of:

[0802]

[0803] In an embodiment, provided herein is a compound having a structure according to Formula (L):

[0804] Where R 2a ,aa,L A ,n,R 4a , R 4b ,y 1 , R 10a and R 10b In accordance with any aspect or embodiment described herein.

[0805] In an embodiment, provided herein is a compound having a structure according to Formula (M):

[0806] Where R 2a ,aa,n,R 4a , R 4b ,y 1 , R 10a and R 10b In accordance with any aspect or embodiment described herein.

[0807] In an embodiment, provided herein is a compound having a structure according to Formula (N):

[0808] Where R 2a ,aa,L A ,n,R 4a , R 4b ,y 1 , Z 1 、p 1 and p 2 In accordance with any aspect or embodiment described herein.

[0809] In an embodiment, provided herein is a compound having a structure according to Formula (O):

[0810] Where R 2a ,aa,n,R 4a , R 4b ,y 1 , Z 1 、p 1 and p 2 In accordance with any aspect or embodiment described herein.

[0811] In an embodiment, provided herein is a compound having a structure according to Formula (P):

[0812] Where R 2a ,aa,L A , n, X and R 1a In accordance with any aspect or embodiment described herein.

[0813] In an embodiment, provided herein is a compound having a structure according to Formula (Q):

[0814] Where R 2a , aa, n, X and R 1a In accordance with any aspect or embodiment described herein.

[0815] In an embodiment, provided herein is a compound having a structure according to Formula (R):

[0816] Where R 2a ,aa,L A , n, Z b 、p 1 、p 2 and R 10a and R 10b In accordance with any aspect or embodiment described herein.

[0817] In an embodiment, provided herein is a compound having a structure according to Formula (S):

[0818] Where R 2a ,aa,n,Z b 、p 1 、p 2 and R 10a and R 10b In accordance with any aspect or embodiment described herein.

[0819] In an embodiment, provided herein is a compound having a structure according to Formula (T):

[0820] where p 1 is 1, 2, 3 or 4 and R 2a ,aa,L A ,n,R 4b and R 8h In accordance with any aspect or embodiment described herein.

[0821] In an embodiment, provided herein is a compound having a structure according to Formula (U):

[0822] where p 1 is 1, 2, 3 or 4 and R 2a ,aa,n,R 4b and R 8h In accordance with any aspect or embodiment described herein.

[0823] In an embodiment, provided herein is a compound having a structure according to Formula (V):

[0824] Where R 2a ,aa,L A ,n,R 4a , R 4b and 1 In accordance with any aspect or embodiment described herein.

[0825] In an embodiment, provided herein is a compound having a structure according to Formula (W):

[0826] Where and R 2a ,aa,n,R 4a , R 4b and 1 In accordance with any aspect or embodiment described herein.

[0827] In an embodiment, provided herein is a compound having a structure according to Formula (X):

[0828] Where R 5N is selected from H, C1-C7 straight chain alkyl and C3-C7 branched chain alkyl, and R 2a ,aa,L A ,n,R 4a , R 4b and 1 In accordance with any aspect or embodiment described herein.

[0829] In an embodiment, provided herein are compounds having a structure according to Formula (Y):

[0830] Where R 5N is selected from H, C1-C7 straight chain alkyl and C3-C7 branched chain alkyl, and R 2a ,aa,n,R 4a , R 4b and 1 In accordance with any aspect or embodiment described herein.

[0831] In an embodiment, provided herein is a compound having a structure according to Formula (Z):

[0832] Where R 5a is pyridyl or pyridazine and R 2a ,aa,L A and n is consistent with any aspect or embodiment described herein.

[0833] In an embodiment, provided herein is a compound having a structure according to Formula (AA):

[0834] Where R 5a is pyridyl or pyridazine and R 2a , aa and n are consistent with any aspect or embodiment described herein.

[0835] In an embodiment, provided herein is a compound having a structure according to Formula (BB):

[0836] Where R 5b is C1–C7 alkyl, C3–C7 cycloalkyl, C1–C7 fluoroalkyl or C3–C7 cyclofluoroalkyl and R 2a ,aa,L A and n is consistent with any aspect or embodiment described herein.

[0837] In an embodiment, provided herein is a compound having a structure according to Formula (CC):

[0838] Where R 5b is C1–C7 alkyl, C3–C7 cycloalkyl, C1–C7 fluoroalkyl or C3–C7 cyclofluoroalkyl and R 2a , aa and n are consistent with any aspect or embodiment described herein.

[0839] In an embodiment, provided herein is a compound having a structure according to Formula (DD):

[0840] Where R 2 ,n,R a and R b In accordance with any aspect or embodiment described herein.

[0841] In an embodiment, provided herein is a compound having a structure according to Formula (EE):

[0842] Where R 2 and n is consistent with any aspect or embodiment described herein.

[0843] In an embodiment, provided herein is a compound having a structure according to Formula (FF):

[0844] Where R 2 and n is consistent with any aspect or embodiment described herein.

[0845] In an embodiment, provided herein is a compound having a structure according to Formula (GG):

[0846] Where R 2 and n is consistent with any aspect or embodiment described herein.

[0847] In an embodiment, provided herein is a compound having a structure according to Formula (HH):

[0848] Where R 2 and n is consistent with any aspect or embodiment described herein.

[0849] In an embodiment, provided herein is a compound having a structure according to Formula (JJ):

[0850] Where R 1 , R 2 and n is consistent with any aspect or embodiment described herein.

[0851] In an embodiment, provided herein is a compound having a structure according to Formula (KK):

[0852] Where R 1 , R 2a , a and n are consistent with any aspect or embodiment described herein.

[0853] In an embodiment, provided herein is a compound having a structure according to Formula (LL):

[0854] Where R 1 , R 2a , a and n are consistent with any aspect or embodiment described herein.

[0855] In an embodiment, provided herein is a compound having a structure according to Formula (MM):

[0856] Where R 1 , R 2a , aa and n are consistent with any aspect or embodiment described herein.

[0857] In an embodiment, provided herein is a compound having a structure according to Formula (NN):

[0858] Among them, X, R 2a , n consistent with any aspect or embodiment described herein.

[0859] In an embodiment, provided herein is a compound having a structure according to Formula (OO):

[0860] Where R 2 ,n,R 6a , R 6b and R 7 In accordance with any aspect or embodiment described herein.

[0861] In an embodiment, provided herein is a compound having a structure according to Formula (PP):

[0862] Where R 2 ,n,R 6c , R 6d and R 7 In accordance with any aspect or embodiment described herein.

[0863] In an embodiment, provided herein is a compound having a structure according to Formula (QQ):

[0864] Where R 8h , R 2a , R 4a , R A , a, aa, and n are as described for any formula, aspect, or embodiment described herein. In an embodiment, R 8h is an unsubstituted C1-C7 alkyl group (e.g., methyl). 4a is hydrogen or unsubstituted C1-C7 alkyl (e.g., R 4a is hydrogen or methyl, ethyl or isopropyl). In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R AWhere present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. 4a The substituted carbon atom has the (R)-configuration. 4a The substituted carbon atom has the (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0865] In an embodiment, provided herein is a compound having a structure according to Formula (RR):

[0866] Where R 8e ,R 2a , a and n are as described for any formula, aspect or embodiment described herein. In an embodiment, R 8e is unsubstituted C1-C7 alkyl (e.g., methyl). In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is a halogen (e.g., -F and / or -Cl). In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration.

[0867] In an embodiment, provided herein is a compound having a structure according to Formula (SS):

[0868] Where R 2a ,R A , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, n is 2. In an embodiment, aa is 0, 1 or 2. In an embodiment, aa is 0. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 1. In an embodiment, R A is a C1-C7 alkyl group (e.g., methyl). In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0869] In an embodiment, provided herein is a compound having a structure according to Formula (TT):

[0870] Where R 2a ,R A ,R 5 , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, R 5 is unsubstituted C1-C7 alkyl (e.g., methyl or ethyl). In an embodiment, n is 2. In an embodiment, a is 0 or 1. In an embodiment, R A is C1-C7 alkyl (e.g., methyl). In an embodiment, aa is 1. In an embodiment, aa is 0, 1 or 2. In an embodiment, aa is 0. In an embodiment, aa is 1. In an embodiment, each R 2a is a halogen (e.g., -F and / or -Cl). In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In an embodiment, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0871] In an embodiment, provided herein is a compound having a structure according to Formula (UU):

[0872] Where R 5 ,R A ,R 2a , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, R 5 is an unsubstituted C1-C7 alkyl group (e.g., methyl, ethyl, isopropyl). 5 is C1-C7 haloalkyl (e.g., CH2CF3). In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R A Where present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0873] In an embodiment, provided herein is a compound having a structure according to Formula (VV):

[0874] Where R A ,R 2a , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R A Where present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0875] In an embodiment, provided herein is a compound having a structure according to Formula (WW):

[0876] Where R 8j ,R 2a ,R A , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, R 8j is unsubstituted C1-C7 alkyl (e.g., methyl or ethyl). In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R A Where present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0877] In an embodiment, provided herein is a compound having a structure according to Formula (XX):

[0878] Where RA ,R 2a , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R A Where present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0879] In an embodiment, provided herein are compounds having a structure according to Formula (YY):

[0880] Where R A ,R 2a , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R A Where present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0881] In an embodiment, provided herein is a compound having a structure according to Formula (ZZ):

[0882] Where R A ,R 2a ,R 8a , R 8b , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, R 8a is hydrogen or unsubstituted C1-C7 alkyl (e.g., methyl). 8bis hydrogen or unsubstituted C1-C7 alkyl (e.g., methyl). In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R A Where present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0883] In an embodiment, provided herein is a compound having a structure according to Formula (AAA):

[0884] Where R A ,R 2a ,R 8a , R 8b , a, aa and n are as described for any formula, aspect or embodiment described herein. In an embodiment, uu is 1 or 2. In an embodiment, n is 2. In an embodiment, aa is 1 or 2. In an embodiment, aa is 1. In an embodiment, each R 2a is halogen (e.g., -F and / or -Cl). In an embodiment, a is 0 or 1. In an embodiment, R A Where present, it is an unsubstituted C1-C7 alkyl group (e.g., methyl). In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (R)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. In embodiments, the C5 carbon of the 2-dihydrofuranone core has an (S)-configuration. A The substituted carbon atom has the (R)-configuration. A The substituted carbon atom has the (S)-configuration.

[0885] Exemplary compounds

[0886] Exemplary compounds according to the formulae described herein (eg, according to formula (I), (I*), (I**), or (II), such as any of formula (A)-(AAA)) include compounds 1-145 as described in Table 1.

[0887] Table 1: Exemplary compounds

[0888]

[0889]

[0890]

[0891]

[0892]

[0893]

[0894]

[0895]

[0896]

[0897]

[0898]

[0899]

[0900]

[0901]

[0902]

[0903]

[0904]

[0905]

[0906]

[0907]

[0908]

[0909]

[0910] General synthetic method for preparing 5-HT7 modulators

[0911] The reagents used to prepare the compounds of the present invention are either commercially available or can be prepared by standard procedures described in the literature. According to the present invention, the compounds in the genus can be prepared by one of the following reaction schemes.

[0912] The compounds disclosed herein can be prepared by methods described in the following applications: International Application No. PCT / US2017 / 061677, filed November 15, 2017; International Application No. PCT / US2013 / 071926, filed November 26, 2013; International Application No. PCT / US2014 / 023400, filed March 11, 2014; International Application No. PCT / US2015 / 023401, filed September 10, 2015; Application No. PCT / US2015 / 049303; International Application No. PCT / US2016 / 031780 filed on May 11, 2016; International Application No. PCT / US2018 / 022581 filed on March 15, 2018; and International Application No. PCT / US2018 / 022574 filed on March 15, 2018, the entire contents of each of these international applications are incorporated herein by reference.

[0913] Additionally, certain exemplary methods are described in Schemes 1-4. In these schemes, the variables in any structure may conform to any aspect or embodiment described herein.

[0914] Solution 1

[0915]

[0916] The compound of formula (a1) is reacted with the compound of formula (a5) (known compound or compound prepared by known method) under the following conditions to obtain the compound of formula (a2): in the presence of a coupling agent such as 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium hexafluorophosphate 3-oxide, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, etc., optionally in the presence of hydroxybenzoic acid. In the presence of triazole, optionally in the presence of 1-hydroxy-7-azabenzotriazole, and optionally in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, N,N-diisopropylethylamine, pyridine, etc., in the presence of a solvent such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally by heating, optionally by microwave irradiation. The compound according to formula (a2) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, etc. in a solvent such as tetrahydrofuran, 1,4-dioxane, dichloromethane, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, etc., optionally by heating, optionally by microwave irradiation, to obtain a compound of formula (a3).

[0917] In the presence of a base such as triethylamine, diisopropylethylamine, pyridine, etc., in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc., optionally by heating, optionally by microwave irradiation, a compound of formula (a3) ​​is reacted with a compound of formula (a4-1) (a known compound or a compound prepared by a known method) to obtain a compound of formula (a4-1a). Alternatively, a compound of formula (a3) ​​is reacted with a compound of formula (a4-2) (a known compound or a compound prepared by a known method, wherein X is substituted with 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc.) in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, etc., in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc., optionally by heating, optionally by microwave irradiation. 1 is chlorine) to give a compound of formula (a4-2a). Alternatively, a compound of formula (a3) ​​is reacted with a compound of formula (a4-2) (a known compound or a compound prepared by a known method, wherein X 1is OH) under the following conditions to obtain a compound of formula (a4-2a): in the presence of a coupling agent such as 3-oxidized hexafluorophosphate 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium, hexafluorophosphate O-(benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, etc., optionally in the presence of hydroxybenzotriazole , optionally in the presence of 1-hydroxy-7-azabenzotriazole and the like, optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine and the like, in the presence of a solvent such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane and the like, optionally by heating, optionally by microwave irradiation.

[0918] Alternatively, a compound of formula (a3) ​​is reacted with a compound of formula (a4-3) (a known compound or a compound prepared by a known method, wherein X is selected from the group consisting of iodine, bromine, chlorine, methanesulfonate and p-toluenesulfonate) under the following conditions to obtain a compound of formula (a4-3a): in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, etc., in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc., optionally by heating, optionally by microwave irradiation.

[0919] Solution 2

[0920]

[0921] The compound of formula (a1) is reacted with the compound of formula (a9) (known compound or compound prepared by known method) under the following conditions to obtain the compound of formula (a6): in the presence of a coupling agent such as 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium hexafluorophosphate 3-oxide, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and the like, optionally at the hydroxy In the presence of benzotriazole, optionally in the presence of 1-hydroxy-7-azabenzotriazole, optionally in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, N,N-diisopropylethylamine, pyridine, etc., in the presence of a solvent such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane, etc., optionally by heating, optionally by microwave irradiation. The compound according to formula (a6) is reacted with an acid such as trifluoroacetic acid, hydrochloric acid, sulfuric acid, etc. in a solvent such as tetrahydrofuran, 1,4-dioxane, dichloromethane, 1,2-dichloroethane, methanol, ethanol, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, etc., optionally by heating, optionally by microwave irradiation, to obtain a compound of formula (a7). The compound of formula (a7) is reacted with a compound of formula (a8-1) (known compound or compound prepared by a known method) in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, etc., in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc., optionally by heating, optionally by microwave irradiation, to obtain a compound of formula (a8-1a). Alternatively, a compound of formula (a7) is reacted with a compound of formula (a8-2) (a known compound or a compound prepared by a known method, wherein X is substituted with 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc.) in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, etc., in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc., optionally by heating, optionally by microwave irradiation. 1 is chlorine) to give a compound of formula (a8-2a). Alternatively, a compound of formula (a7) is reacted with a compound of formula (a8-2) (a known compound or a compound prepared by a known method, wherein X 1is OH) under the following conditions to obtain a compound of formula (a4-8a): in the presence of a coupling agent such as 3-oxidized hexafluorophosphate 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium, hexafluorophosphate O-(benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, etc., optionally in the presence of hydroxybenzotriazole , optionally in the presence of 1-hydroxy-7-azabenzotriazole and the like, optionally in the presence of a base such as triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine and the like, in the presence of a solvent such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane and the like, optionally by heating, optionally by microwave irradiation.

[0922] Alternatively, a compound of formula (a7) is reacted with a compound of formula (a8-3) (a known compound or a compound prepared by a known method, wherein X is selected from the group consisting of iodine, bromine, chlorine, methanesulfonate and p-toluenesulfonate) under the following conditions to obtain a compound of formula (a8-3a): in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, etc., in a solvent such as dichloromethane, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, etc., optionally by heating, optionally by microwave irradiation.

[0923] Solution 3

[0924]

[0925] The compound of formula (a1) is reacted with a compound of formula (a10) (a known compound or a compound prepared by a known method, wherein X is selected from the group consisting of iodine, bromine, chlorine, methanesulfonate and p-toluenesulfonate) under the following conditions to obtain a compound of formula (a10-1): in the presence of a palladium catalyst such as palladium acetate (II), tetrakis(triphenylphosphine)palladium(0), dichlorobis(triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), etc. In the presence of organic phosphine such as 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl, 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl, 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl, (2-biphenyl)dicyclohexylphosphine, (2-biphenyl)di-tert-butylphosphine, 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl, 2 -di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl, 2′-dicyclohexylphosphino-2,6-dimethoxy-1,1′-biphenyl-3-sulfonate sodium, 2-di-tert-butylphosphino-2′-methylbiphenyl, 2-dicyclohexylphosphino-2′-methylbiphenyl, 2′-(di-tert-butylphosphino)-N,N-dimethylbiphenyl-2-amine, 2′-(diphenylphosphino)-N,N′-dimethyl- (1,1′-biphenyl)-2-amine and the like, optionally in the presence of a base such as sodium carbonate, lithium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, triethylamine, N,N-diisopropylethylamine, pyridine, 2,6-lutidine and the like, in a solvent such as tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, chloroform, 1,2-dichloroethane, 1,2-dimethoxyethane and the like, optionally by heating, optionally by microwave irradiation.

[0926] Solution 4

[0927]

[0928] The compound of formula (a1) is reacted with the compound of formula (a12) (known compound or compound prepared by known method) under the following conditions to obtain the compound of formula (a11): in the presence of a coupling agent such as 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium hexafluorophosphate 3-oxide, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, etc., optionally in the presence of hydroxybenzoic acid. In the presence of triazole, optionally in the presence of 1-hydroxy-7-azabenzotriazole and the like, and optionally in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, N,N-diisopropylethylamine, pyridine and the like, in the presence of a solvent such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylacetamide, dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, 1,2-dimethoxyethane and the like, optionally by heating, optionally by microwave irradiation.

[0929] Treatment

[0930] In embodiments, the compounds described herein are selective modulators of serotonin 5-HT7 receptors. In embodiments, the compounds described herein can more effectively bind to serotonin 5-HT7 receptors than other targets (e.g., other serotonin receptors). In embodiments, the compounds described herein can selectively bind to serotonin 5-HT7 receptors in specific tissues or organs.

[0931] For example, the compounds described herein can selectively bind to serotonin 5-HT7 receptors in the intestine of a subject.Therefore, the compounds described herein can be used to treat or prevent inflammatory bowel disease (IBD) or enteritis.

[0932] In other embodiments, the compounds described herein may have particularly advantageous properties for effective treatment (e.g., treatment of any disease or condition described herein). For example, in the treatment of CNS or mental disorders, the compounds described herein may exhibit advantageous effective blood-brain barrier permeability. Alternatively, in the treatment of non-CNS or non-mental disorders, the compounds described herein will not have high blood-brain barrier permeability (e.g., off-target effects will be reduced). Without being bound by theory, the molecular elements of the compounds may be an effective strategy for obtaining desired biological targeting.

[0933] There is evidence for a role for the 5-HT7 receptor in a variety of medical conditions. Modulators of 5-HT7 receptor activity may have beneficial effects in patients suffering from these conditions. Diseases in which 5-HT7 dysregulation plays a role and modulation of 5-HT7 receptor activity by therapeutic agents may be a viable approach for therapeutic relief include, but are not limited to, circadian rhythm disorders, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral vascular disease, migraine (Vanhoenacker, P. et al., Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulatory disorders, learning disorders, memory disorders, hippocampal signaling disorders, sleep disorders (WO20100197700), attention deficit / hyperactivity disorder (ADHD) (WO20100069390), anxiety disorders, avoidant personality disorder, premature ejaculation, eating disorders, premenstrual syndrome, premenstrual dysphoric disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), enteritis (WO 2012058769, Khan, WI et al., Journal of Immunology, 2013, 190, 4795-4804), epilepsy, epilepsy (Epilepsy Research (2007) 75, 39), drug addiction, alcohol addiction (Hauser, SR et al., Frontiers in Neuroscience, 2015, 8, 1-9), breast cancer (Gautam, J. Molecular Cancer, 2016, 15, 75, 1-14, Gautam, J. Breast Cancer Research and Treatment, 2017, 161, 29-40), liver fibrosis, chronic liver damage (Halici, Z. International Immunopharmacology, 2017, 43, 227-235), hepatocellular carcinoma (Bian, ZX Molecular Oncology, 2016, 10, 195-212), small intestinal neuroendocrine tumors (Modlin, IM Cancer Science, 2013, 104, 7, 844-855) and lung injury (Halici, Z. Immunology, 2013, 1271-1283).

[0934] Therefore, there is a long-standing need for new 5-HT7 modulators that will provide therapeutic relief to patients suffering from diseases associated with dysregulated 5-HT receptor 7 activity. The present invention addresses the need to identify novel 5-HT7 modulators capable of treating diseases associated with dysregulated 5-HT receptor 7 activity. The present invention addresses the need to develop new therapeutic agents for the treatment and prevention of circadian rhythm disorders, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral vascular disease, migraine, neuropathic pain, peripheral pain, allodynia, temperature regulation disorders, learning disorders, memory disorders, hippocampal signaling disorders, sleep disorders, attention deficit / hyperactivity disorder, anxiety disorders, avoidant personality disorder, premature ejaculation, eating disorders, premenstrual syndrome, premenstrual dysphoric disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), enteritis, epilepsy, epileptic disorders, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestinal neuroendocrine tumors and lung injury.

[0935] The 5-hydroxytryptamine receptor 7 activity modulator of the present invention can treat and prevent diseases associated with 5-hydroxytryptamine receptor 7 activity disorders, such as circadian rhythm disorders, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral vascular disease, migraine, neuropathic pain, peripheral pain, allodynia, temperature regulation disorders, learning disorders, memory disorders, hippocampal signaling disorders, sleep disorders, attention deficit / hyperactivity disorder, anxiety disorders, avoidant personality disorder, premature ejaculation, eating disorders, premenstrual syndrome, premenstrual dysphoric disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), enteritis, epilepsy, epilepsy, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver damage, hepatocellular carcinoma, small intestinal neuroendocrine tumors and lung damage. 5-hydroxytryptamine receptor 7 has been found to play a role in a variety of medical diseases, and therefore, 5-HT7 receptor activity modulators may have beneficial effects on patients suffering from these diseases.Diseases in which 5-HT7 dysregulation plays a role and modulation of 5-HT7 receptor activity by therapeutic agents may be a viable approach for therapeutic relief include, but are not limited to, circadian rhythm disorders, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral vascular disease, migraine (Vanhoenacker, P. et al., Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulatory disorders, learning disorders, memory disorders, hippocampal signaling disorders, sleep disorders (WO20100197700), attention deficit / hyperactivity disorder (ADHD) (WO20100069390), anxiety disorders, avoidant personality disorder, premature ejaculation, eating disorders, premenstrual syndrome, premenstrual dysphoric disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), enteritis (WO 2012058769), epilepsy, epilepsy (Epilepsy Research (2007) 75, 39), drug addiction, alcohol addiction (Hauser, SR et al., Frontiers in Neuroscience, 2015, 8, 1-9), breast cancer (Gautam, J. Molecular Cancer, 2016, 15, 75, 1-14, Gautam, J. Breast Cancer Research and Treatment, 2017, 161, 29-40), liver fibrosis, chronic liver damage (Halici, Z. International Immunopharmacology, 2017, 43, 227-235), hepatocellular carcinoma (Bian, ZX Molecular Oncology, 2016, 10, 195-212), small intestinal neuroendocrine tumors (Modlin, IM Cancer Science, 2013, 104, 7, 844-855) and lung injury (Halici, Z. Immunology, 2013, 1271-1283).

[0936] Without wishing to be bound by theory, it is believed that the 5-hydroxytryptamine receptor 7 receptor activity modulators of the present invention can improve, alleviate or otherwise control diseases associated with dysregulated 5-hydroxytryptamine receptor 7 activity. These diseases include, but are not limited to, circadian rhythm disorders, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral vascular disease, migraine, neuropathic pain, peripheral pain, allodynia, temperature regulation disorders, learning disorders, memory disorders, hippocampal signaling disorders, sleep disorders, attention deficit / hyperactivity disorder, anxiety disorders, avoidant personality disorder, premature ejaculation, eating disorders, premenstrual syndrome, premenstrual dysphoric disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), enteritis, epilepsy, epilepsy, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver damage, hepatocellular carcinoma, small intestinal neuroendocrine tumors and lung damage.

[0937] In embodiments, the disease is depression, schizophrenia, anxiety, or bipolar disorder. In embodiments, the disease is depression. In embodiments, the disease is schizophrenia. In embodiments, the disease is anxiety. In embodiments, the disease is bipolar disorder.

[0938] In an embodiment, the disorder is attention-deficit / hyperactivity disorder.

[0939] In an embodiment, the disorder is avoidant personality disorder.

[0940] In an embodiment, the disorder is seasonal affective disorder.

[0941] In embodiments, the disease is a circadian rhythm disorder or a hippocampal signaling disorder. In embodiments, the disease is a circadian rhythm disorder. In embodiments, the disease is a hippocampal signaling disorder.

[0942] In embodiments, the disease is neurogenic inflammation.

[0943] In embodiments, the disease is neuropathic pain, peripheral pain, or allodynia. In embodiments, the disease is neuropathic pain. In embodiments, the disease is peripheral pain. In embodiments, the disease is allodynia.

[0944] In an embodiment, the disorder is migraine.

[0945] In embodiments, the disease is epilepsy or an epileptic disorder. In embodiments, the disease is epilepsy. In embodiments, the disease is an epileptic disorder.

[0946] In embodiments, the disease is a learning disorder or a memory disorder. In embodiments, the disease is a learning disorder. In embodiments, the disease is a memory disorder.

[0947] In embodiments, the disease is an eating disorder.

[0948] In embodiments, the disease is drug addiction or alcohol addiction.

[0949] In an embodiment, the disease is a sleep disorder.

[0950] In embodiments, the disease is hypertension or peripheral vascular disease. In embodiments, the disease is hypertension. In embodiments, the disease is peripheral vascular disease.

[0951] In an embodiment, the disease is a thermoregulatory disorder.

[0952] In an embodiment, the disorder is premature ejaculation.

[0953] In embodiments, the disease is premenstrual syndrome or premenstrual dysphoric disorder. In embodiments, the disease is premenstrual syndrome. In embodiments, the disease is premenstrual dysphoric disorder.

[0954] In embodiments, the disease is inflammatory bowel disease (IBD) or enteritis. In embodiments, the disease is inflammatory bowel disease (IBD). In embodiments, the disease is enteritis.

[0955] In embodiments, the disease is breast cancer.

[0956] In embodiments, the disease is liver fibrosis, chronic liver damage, or hepatocellular carcinoma. In embodiments, the disease is liver fibrosis. In embodiments, the disease is chronic liver damage. In embodiments, the disease is hepatocellular carcinoma.

[0957] In an embodiment, the disease is a small intestinal neuroendocrine tumor.

[0958] In embodiments, the disease is lung injury.

[0959] In embodiments, the disease is inflammatory bowel disease (IBD).

[0960] Preparations (pharmaceutical compositions) of 5-HT7 modulators

[0961] The present invention also relates to a composition or formulation comprising a 5-hydroxytryptamine receptor 7 activity modulator according to the present invention. Generally speaking, the composition of the present invention comprises: an effective amount of one or more disclosed compounds and salts thereof according to the present invention, which can effectively provide modulation of 5-hydroxytryptamine receptor 7 activity; and one or more excipients.

[0962] For the purposes of the present invention, the terms "excipient" and "carrier" are used interchangeably in the specification of the present invention, and the terms are defined herein as "ingredients used in the practice of formulating safe and effective pharmaceutical compositions."

[0963] Formulators should understand that excipients are primarily used to provide safe, stable and functional drugs, not only as a part of the entire delivery vehicle, but also as a means of achieving effective absorption of the recipient of the active ingredient. Excipients can work simply and directly like inert fillers, or excipients as used herein can be part of a pH stabilizing system or coating to ensure that the ingredients are safely delivered to the stomach. Formulators can also take advantage of the fact that the compounds of this invention have improved cellular efficacy, pharmacokinetic properties, and improved oral bioavailability.

[0964] The present teachings also provide pharmaceutical compositions comprising at least one compound described herein and one or more pharmaceutically acceptable carriers, excipients or diluents. Examples of such carriers are well known to those skilled in the art and can be prepared according to acceptable pharmaceutical methods, such as those described in Remington's Pharmaceutical Sciences, 17th edition, Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985), the entire disclosure of which is incorporated herein by reference for all purposes. As used herein, "pharmaceutically acceptable" refers to a substance that can be used for pharmaceutical applications from a toxicological perspective and does not interact adversely with active ingredients. Therefore, a pharmaceutically acceptable carrier is a carrier that is compatible with other ingredients in the formulation and is biologically acceptable. Supplementary active ingredients can also be incorporated into pharmaceutical compositions.

[0965] The compounds of the present teachings can be administered orally or parenterally, alone or in combination with conventional pharmaceutical carriers. Applicable solid carriers may include one or more substances that may also be used as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet disintegrating agents, or encapsulating materials. The compounds can be formulated in a conventional manner, for example, in a manner similar to that used for known 5-hydroxytryptamine receptor 7 activity modulators. Oral formulations containing the compounds disclosed herein may include any commonly used oral forms, including tablets, capsules, oral dosage forms, lozenges, pastilles and oral liquids, suspensions or solutions. In powders, the carrier may be a finely divided solid, which is a mixture with a finely divided compound. In tablets, the compounds disclosed herein may be mixed with a carrier having the necessary compression properties in a suitable proportion and pressed into the desired shape and size. Powders and tablets may contain up to 99% of the compound.

[0966] Capsules may contain a mixture of one or more compounds disclosed herein with inert fillers and / or diluents such as pharmaceutically acceptable starch (e.g., corn, potato or tapioca starch), sugars, artificial sweeteners, powdered cellulose (e.g., crystalline and microcrystalline cellulose), flours, gelatin, gums, and the like.

[0967] Tablet formulations available can be prepared by conventional compression, wet granulation or dry granulation methods, and use pharmaceutically acceptable diluents, binders, lubricants, disintegrants, surface modifiers (including surfactants), suspending agents or stabilizers, including but not limited to magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugar, lactose, dextrin, starch, gelatin, cellulose, methylcellulose, microcrystalline cellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, polyvinyl pyrrolidine, alginic acid, gum arabic, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting wax and ion exchange resin. Surface modifiers include nonionic and anionic surface modifiers. Representative examples of surface modifiers include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium lauryl sulfate, magnesium aluminum silicate, and triethanolamine. The oral formulations herein may use standard delayed or extended release formulations to alter the absorption of the compound. The oral formulations may also include administering the compounds disclosed herein in water or juice, containing appropriate solubilizers or emulsifiers as needed.

[0968] Liquid carriers can be used to prepare solutions, suspensions, emulsions, syrups, elixirs and for inhalation delivery. The compounds of the present invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent or a mixture of the two or a pharmaceutically acceptable oil or fat. The liquid carrier may contain other suitable pharmaceutical additives, such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickeners, colorants, viscosity modifiers, stabilizers and osmotic regulators. Examples of liquid carriers for oral and parenteral administration include, but are not limited to, water (especially containing additives as described herein, such as cellulose derivatives, such as sodium carboxymethylcellulose solution), alcohols (including monohydric alcohols and polyols, such as diols) and their derivatives, and oils (e.g., fractionated coconut oil and peanut oil). For parenteral administration, the carrier can be an oily ester, such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in compositions in sterile liquid form for parenteral administration. The liquid carrier for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.

[0969] Liquid pharmaceutical compositions (which are sterile solutions or suspensions) can be used, for example, by intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration can be in liquid or solid form.

[0970] Preferably, the pharmaceutical composition is a unit dosage form in the form of tablets, capsules, powders, solutions, suspensions, emulsions, granules or suppositories. In this form, the pharmaceutical composition can be subdivided into unit doses containing an appropriate amount of compound. The unit dosage form can be a packaged composition, such as a packaged powder, vial, ampoule, pre-filled syringe or a pouch containing a liquid. Alternatively, the unit dosage form can be a capsule or tablet itself, or it can be any such composition of the appropriate number of packaged forms. This unit dosage form can contain about 1 mg / kg compound to about 500 mg / kg compound, and can be administered in a single dose or two or more doses. These doses can be used in any manner that can be used to guide the compound to the recipient's bloodstream, including oral, via implants, parenteral (including intravenous, intraperitoneal and subcutaneous injections), rectal, vaginal and transdermal.

[0971] When used to treat or inhibit a specific disease state or condition, it should be understood that the effective dose can vary according to the specific compound used, the mode of administration, the severity of the condition being treated, and various physical factors associated with the individual being treated. In therapeutic applications, the compound of the present teachings can be applied to a patient who has suffered from the disease in an amount sufficient to cure or at least partially improve the symptoms of the disease or its complications. The dosage used to treat a specific individual must usually be determined subjectively by the attending physician. The variables involved include the patient's specific condition and its state, as well as body size, age, and reaction pattern.

[0972] In some cases, it is desirable to use devices such as, but not limited to, metered dose inhalers, breath-operated inhalers, multi-dose dry powder inhalers, pumps, squeeze-actuated atomizing spray dispensers, aerosol dispensers, and aerosol sprayers to apply the compound directly to the patient's airway. For administration by intranasal or intrabronchial inhalation, the compound of the present teaching content can be formulated into a liquid composition, a solid composition, or an aerosol composition. For example, a liquid composition may include one or more compounds of the present teaching content dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents, and may be administered by, for example, a pump or an squeeze-actuated atomizing spray dispenser. The solvent may be, for example, isotonic saline or antibacterial water. For example, a solid composition may be a powder preparation containing one or more compounds of the present teaching content mixed with lactose or other inert powders that can be used for intrabronchial use, and may be administered by, for example, an aerosol dispenser or a device that can destroy or pierce a capsule that encapsulates a solid composition and delivers a solid composition for inhalation. For example, an aerosol composition may include one or more compounds of the present teaching content, a propellant, a surfactant, and a cosolvent, and may be administered by, for example, a metering device. The propellant may be a chlorofluorocarbon (CFC), a hydrofluoroalkane (HFA), or other physiologically and environmentally acceptable propellant.

[0973] The compounds described herein can be administered parenterally or intraperitoneally. Solutions or suspensions of these compounds or their pharmaceutically acceptable salts, hydrates or esters can be prepared in water appropriately mixed with a surfactant such as hydroxypropylcellulose. Dispersants can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under normal storage and use conditions, these preparations typically contain preservatives to inhibit the growth of microorganisms.

[0974] The pharmaceutical form suitable for injection can include sterile aqueous solution or dispersion and sterile powder for the temporary preparation of sterile injectable solution or dispersion. In some embodiments, the form can be sterile and its viscosity allows it to flow through the syringe. The form is preferably stable under manufacturing and storage conditions, and can prevent the contamination of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol), their suitable mixture and vegetable oil.

[0975] The compounds described herein can be administered transdermally, i.e., through the surface of the body and the inner linings of body passages, including epithelial and mucosal tissues. Such administration can be performed using the compounds of the present teachings (including pharmaceutically acceptable salts, hydrates or esters thereof) in lotions, creams, foams, patches, suspensions, solutions and suppositories (rectal and vaginal).

[0976] Transdermal administration can be accomplished by using a transdermal patch containing a compound (e.g., a compound disclosed herein) and a carrier that may be inert to the compound and nontoxic to the skin, and can allow the compound to be delivered for systemic absorption into the bloodstream via the skin. The carrier can take any number of forms, such as creams and ointments, pastes, gels, and occlusive devices. Creams and ointments can be viscous liquids or semisolid emulsions of the oil-in-water or water-in-oil type. Pastes composed of absorbent powders dispersed in petroleum or hydrophilic petroleum containing the compound may also be suitable. Various occlusive devices can be used to release the compound into the bloodstream, such as a semipermeable membrane covering a reservoir containing the compound with or without a carrier, or a matrix containing the compound. Other occlusive devices are known in the literature.

[0977] The compounds described herein can be administered rectally or vaginally in the form of conventional suppositories. Suppository formulations can be made from traditional materials (including cocoa butter with or without wax added to change the melting point of the suppository) and glycerol. Water-soluble suppository bases, such as polyethylene glycols of various molecular weights, can also be used.

[0978] Lipid formulations or nanocapsules can be used to introduce compounds of the present teachings into host cells in vitro or in vivo. Lipid formulations and nanocapsules can be prepared by methods known in the art.

[0979] In order to increase the effectiveness of the compounds of the present teachings, it is desirable to combine the compounds with other agents that can effectively treat the target disease. For example, other active compounds (i.e., other active ingredients or agents) that can effectively treat the target disease can be administered together with the compounds of the present teachings. Other agents can be administered simultaneously or at different times with the compounds disclosed herein.

[0980] The compounds of the present teachings can be used to treat or inhibit pathological conditions or disorders in mammals (e.g., human subjects). Therefore, the present teachings provide methods for treating or inhibiting pathological conditions or disorders by providing to mammals compounds of the present teachings (including pharmaceutically acceptable salts thereof) or pharmaceutical compositions comprising one or more compounds of the present teachings in combination or association with a pharmaceutically acceptable carrier. The compounds of the present invention can be administered alone or in combination with other therapeutically effective compounds or therapies for treating or inhibiting pathological conditions or disorders.

[0981] Non-limiting examples of compositions according to the present invention include about 0.001 mg to about 1000 mg of one or more compounds according to the present invention and one or more excipients; about 0.01 mg to about 100 mg of one or more compounds according to the present invention and one or more excipients; and about 0.1 mg to about 10 mg of one or more compounds according to the present invention and one or more excipients.

[0982] Example

[0983] The practice of the present invention is illustrated by the following non-limiting examples.

[0984] Synthesis of 5-HT7 modulators

[0985] The compounds of the present invention can be prepared by methods known in the art. Exemplary methods are described in the following applications: International Application No. PCT / US2017 / 061677 filed on November 15, 2017; International Application No. PCT / US2013 / 071926 filed on November 26, 2013; International Application No. PCT / US2014 / 023400 filed on March 11, 2014; International Application No. PCT / US2015 / 049303 filed on September 10, 2015; International Application No. PCT / US2016 / 031780 filed on May 11, 2016; International Application No. PCT / US2018 / 022581 filed on March 15, 2018; and International Application No. PCT / US2018 / 022574 filed on March 15, 2018.

[0986] The examples provided below provide representative methods for preparing exemplary compounds of the invention. One skilled in the art will know how to substitute appropriate reagents, starting materials and purification methods known to those skilled in the art in order to prepare the compounds of the invention.

[0987] Synthesis and characterization of intermediates

[0988]

[0989] Preparation of (R)-tert-butyl 3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: To a vial was added (R)-tert-butyl 1-oxo-3-(2-(tosyloxy)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (1.5 g, 3.31 mmol, 1 eq) and (S)-1-(4-fluorophenyl)-3-methylpiperazine (1.35 g, 6.95 mmol, 2.1 eq) which were then dissolved in acetonitrile (33 mL). K2CO3 (1.14 g, 8.2 mmol, 2.5 eq) was then added and the reaction was stirred at 80°C overnight before being cooled to 23°C. The mixture was filtered, washed with acetonitrile, and the filtrate was concentrated in vacuo to give the crude product, which was further purified by column chromatography (MeOH / dichloromethane, 0%-10%). LC / MS [M+H] = m / z 476.2

[0990]

[0991] Preparation of (R)-tert-butyl 3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except that 1-(4-fluorophenyl)piperazine was used instead of (S)-1-(4-fluorophenyl)-3-methylpiperazine. LC / MS [M+H] = m / z 462.2

[0992]

[0993] Preparation of (R)-tert-butyl 3-(2-((R)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except that (R)-1-(4-fluorophenyl)-3-methylpiperazine was used instead of (S)-1-(4-fluorophenyl)-3-methylpiperazine. LC / MS [M+H] = m / z 476.2

[0994]

[0995] Preparation of (R)-tert-butyl 3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except that 1-(3-chlorophenyl)piperazine was used instead of (S)-1-(4-fluorophenyl)-3-methylpiperazine. LC / MS [M+H] = m / z 478.2

[0996]

[0997] Preparation of (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-1-one: A 6M solution of HCl in methanol was prepared by adding acetyl chloride (1.2 mL) to methanol (3 mL). (R)-tert-butyl 3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.127 g, 0.267 mmol, 1.0 equiv) was dissolved in the prepared 6M HCl in methanol (3 mL) and stirred at 23 °C for 30 min, then diluted with methanol and concentrated in vacuo to give the crude product as the diHCl salt. The crude product was obtained by stirring with Amberlite IRN-78 base resin in methanol for 15 minutes, then filtered and concentrated in vacuo. LC / MS [M+H] = m / z 376.2

[0998]

[0999] Preparation of (R)-3-(2-((R)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one except Replace (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester with (R)-3-(2-((R)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid tert-butyl ester. LC / MS [M+H] = m / z 376.2

[1000]

[1001] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure used for (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, except that (R)-tert-butyl 3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate was used instead of tert-butyl 3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate. LC / MS [M+H] = m / z 362.2

[1002]

[1003] Preparation of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure used for (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, except that (R)-tert-butyl 3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate was used instead of tert-butyl 3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate. LC / MS [M+H] = m / z 378.2

[1004]

[1005] Preparation of (R)-tert-butyl(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate: The reaction was performed in oven-dried glassware under nitrogen atmosphere. N-(tert-Butyloxycarbonyl)glycine (13.8 mg, 0.078 mmol, 1.05 equiv) was added to a vial and dissolved in dimethylformamide (700 μL). Next, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (31.3 mg, 0.082 mmol, 1.1 equiv) and N,N-diisopropylethylamine (39 mg, 0.3 mmol, 4 equiv) were added and the resulting solution was stirred for 15 minutes at 23° C. In a separate vial, a solution of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride (33.3 mg, 0.074 mmol, 1.0 equiv), dimethylformamide (300 μL) and N,N-diisopropylethylamine (17.3 mg, 0.13 mmol, 2.2 equiv) was prepared. The two solutions were combined and stirred at 23°C for 30 minutes, then diluted with methanol (5 mL) and concentrated in vacuo. The resulting residue was suspended in saturated NaHCO3 (5 mL) and extracted with dichloromethane (3×10 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the crude product, which was further purified by column chromatography (methanol / dichloromethane, 0%-10%). LC / MS [M+H] = m / z 535.3

[1006]

[1007] Preparation of tert-butyl (R)-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate: Prepare tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)carbamate according to the method for (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)carbamate. The title compound was prepared by the same procedure as tert-butyl 2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride except that (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 519.3

[1008]

[1009] Preparation of tert-butyl ((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)carbamate: Prepare tert-butyl ((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)carbamate according to the method for (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)amino The title compound was prepared by the same procedure as tert-butyl formate, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and (tert-butoxycarbonyl)-L-alanine was substituted for N-(tert-butoxycarbonyl)glycine. LC / MS [M+H] = m / z 533.3

[1010]

[1011] Preparation of tert-butyl ((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)carbamate: Prepare tert-butyl ((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)carbamate according to the method for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. The title compound was prepared by the same procedure as described for the butyl ester, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and (S)-2-((tert-butoxycarbonyl)amino)butyric acid was substituted for N-(tert-butoxycarbonyl)glycine. LC / MS [M+H] = m / z 547.3

[1012]

[1013] Preparation of tert-butyl ((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)carbamate: Prepare tert-butyl ((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)carbamate according to the method for (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl) The title compound was prepared by the same procedure as tert-butyl carbamate, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and (tert-butoxycarbonyl)-L-valine was substituted for N-(tert-butoxycarbonyl)glycine. LC / MS [M+H] = m / z 561.3

[1014]

[1015] Preparation of tert-butyl ((S)-1-((R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)carbamate: Prepare tert-butyl ((S)-1-((R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)carbamate according to the method for (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl) The title compound was prepared by the same procedure as tert-butyl carbamate, except that (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was substituted for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and (tert-butoxycarbonyl)-L-alanine was substituted for N-(tert-butoxycarbonyl)glycine. LC / MS [M+H] = m / z 547.3

[1016]

[1017] Preparation of tert-butyl (R)-(1-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)carbamate: The title compound was prepared according to the procedure for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate, except that 2-(boc-amino)isobutyric acid was used instead of N-(tert-butoxycarbonyl)glycine. LC / MS [M+H] = m / z 563.3

[1018]

[1019] Preparation of tert-butyl (R)-(1-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)carbamate: Prepare tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)carbamate according to the method for (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxopropan-2-yl)carbamate. The title compound was prepared by the same procedure as tert-butyl)ethyl)carbamate, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one and 2-(boc-amino)isobutyric acid was used instead of N-(tert-butoxycarbonyl)glycine. LC / MS [M+H] = m / z 547.3

[1020] Synthesis and characterization of 5-HT7 modulators

[1021]

[1022] Preparation of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride: Prepare a 6M methanolic solution of HCl by adding acetyl chloride (6 mL) to methanol (15 mL). (R)-tert-butyl(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate (0.607 g, 0.119 mmol, 1.0 equiv) was dissolved in the prepared 6M methanolic HCl solution (13 mL) and stirred at 23 °C for 45 min, then diluted with methanol and concentrated in vacuo to give the crude product as the diHCl salt. LC / MS [M+H] = m / z 435.2

[1023]

[1024] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride: The title compound was prepared according to the procedure used for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that (R)-( Tert-butyl 2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate was used instead of (R)-tert-butyl (2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. LC / MS [M+H] = m / z 419.2

[1025]

[1026] Preparation of (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)acetamide: A solution of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride (31.6 mg, 0.062 mmol, 1 eq), dichloromethane (1.5 mL) and triethylamine (28.5 mg, 0.24 mmol, 4 eq) was cooled to 0°C, and then acetyl chloride (5.0 mg. 0.062 mmol, 1 eq) was added to the solution. The reaction solution was warmed to 23°C and stirred for 15 minutes. The reaction mixture was diluted with methanol (-2 mL), concentrated in vacuo, and further purified by C18 column chromatography (ACN / H2O, 0%-100%, w / 0.1% NH4OH). LC / MS [M+H] = m / z 477.2

[1027]

[1028] Preparation of (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)acetamide: Follow the procedure for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)acetamide. The title compound was prepared by the same procedure as (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 461.2

[1029]

[1030] Preparation of (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)methanesulfonamide: A solution of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride (431 mg, 0.845 mmol, 1 eq), dichloromethane (17 mL) and triethylamine (516 mg, 5.1 mmol, 6 eq) was cooled to 0°C, and then methanesulfonyl chloride (117 mg. 1.02 mmol, 1.2 eq) was added to the solution. The reaction solution was warmed to 23°C and stirred for 15 minutes. The reaction mixture was diluted with methanol (-10 mL), concentrated in vacuo, and further purified by C18 column chromatography (ACN / H2O, 0%-100%, w / 0.1% NH4OH). LC / MS [M+H] = m / z 513.2

[1031]

[1032] Preparation of (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)methanesulfonamide: Prepare (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)methanesulfonamide according to the method for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)methanesulfonamide. The title compound was prepared by the same procedure as (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 497.2

[1033]

[1034] Preparation of (R)-8-(2-amino-2-methylpropanoyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure used for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that (R)-(1 -tert-butyl (3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)carbamate was used instead of (R)-tert-butyl (2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. In addition, the product was obtained by stirring a solution with Amberlite IRN-78 base resin in methanol for 15 minutes, then filtering and concentrating in vacuo. LC / MS [M+H] = m / z 447.2

[1035]

[1036] Preparation of (R)-8-(2-amino-2-methylpropanoyl)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure used for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that (R)-(1 -tert-butyl (3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)carbamate was used instead of (R)-tert-butyl (2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. In addition, the product was obtained by stirring a solution with Amberlite IRN-78 base resin in methanol for 15 minutes, then filtering and concentrating in vacuo. LC / MS [M+H] = m / z 463.2

[1037]

[1038] Preparation of (R)-N-(1-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)acetamide: Prepare (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)acetamide according to the method for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2 The title compound was prepared by the same procedure as described above with respect to 4-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride except that (R)-8-(2-amino-2-methylpropanoyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 488.2

[1039]

[1040] Preparation of (R)-N-(1-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)acetamide: Prepare (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)acetamide according to the method for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2 The title compound was prepared by the same procedure as described above with respect to 4-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used. LC / MS [M+H] = m / z 504.2

[1041]

[1042] Preparation of (R)-N-(1-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)pivalamide: Prepare (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)pivalamide according to the method for (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2 The title compound was prepared by the same procedure as described above with respect to 4-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used. LC / MS [M+H] = m / z 531.3

[1043]

[1044] Preparation of (R)-N-(1-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)pivalamide: Prepare (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-methyl-1-oxopropan-2-yl)pivalamide according to the method for (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2 The title compound was prepared by the same procedure as described above with respect to 4-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used. LC / MS [M+H] = m / z 547.3

[1045]

[1046] Preparation of (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)pivalamide: The reaction was carried out in oven-dried glassware under a nitrogen atmosphere. Sodium pivalate (21.8 mg, 0.17 mmol, 1.05 eq) was added to a vial and dissolved in dimethylformamide (1.5 mL). Next, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxidohexafluorophosphate (70 mg, 0.18 mmol, 1.1 eq) and N,N-diisopropylethylamine (86.3 mg, 0.67 mmol, 4 eq) were added and the resulting solution was stirred at 23 °C for 15 minutes. In a separate vial, a solution of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride (81.2 mg, 0.16 mmol, 1.0 equiv), dimethylformamide (400 μL) and N,N-diisopropylethylamine (48 mg, 0.37 mmol, 2.2 equiv) was prepared. The two solutions were combined and stirred at 23°C for 30 minutes, then diluted with methanol (5 mL) and concentrated in vacuo. The resulting residue was suspended in saturated NaHCO3 (5 mL) and extracted with dichloromethane (3×10 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the crude product, which was further purified by C18 column chromatography (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS [M+H] = m / z 503.3

[1047]

[1048] Preparation of (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)pivalamide: Prepare (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)pivalamide according to the method for (R)-N-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)pivalamide. The title compound was prepared by the same procedure as (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used instead of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 519.3

[1049]

[1050] Preparation of (R)-8-(dimethylglycyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: According to the procedure for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate The title compound was prepared except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and N,N-dimethylglycine was used instead of N-(tert-butoxycarbonyl)glycine. In addition, the purification method was replaced by column chromatography using a C18 column. (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS[M+H]=m / z 447.3

[1051]

[1052] Preparation of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(dimethylglycyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate, except that N,N-dimethylglycine was used instead of N-(tert-butoxycarbonyl)glycine. In addition, the purification method was replaced by column chromatography using a C18 column. (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS [M+H] = m / z 463.3

[1053]

[1054] Preparation of (R)-8-(2-(dimethylamino)-2-methylpropanoyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: Prepare (R)-8-(2-(dimethylamino)-2-methylpropanoyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one according to the method for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate The title compound was prepared by the same process as described above, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and 2-(dimethylamino)-2-methylpropionic acid was used instead of N-(tert-butoxycarbonyl)glycine. In addition, column chromatography using a C18 column was used instead of the purification method. (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS[M+H]=m / z 475.3

[1055]

[1056] Preparation of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(2-(dimethylamino)-2-methylpropanoyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate, except that 2-(dimethylamino)-2-methylpropionic acid was used instead of N-(tert-butoxycarbonyl)glycine. In addition, the purification method was replaced by column chromatography using a C18 column. (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS [M+H] = m / z 491.3

[1057]

[1058] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(2-morpholinoacetyl)-2-oxa-8-azaspiro[4.5]decan-1-one: Prepare (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(2-morpholinoacetyl)-2-oxa-8-azaspiro[4.5]decan-1-one according to the method for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. The title compound was prepared by the following procedure, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and morpholin-4-yl acetic acid was used instead of N-(tert-butoxycarbonyl)glycine. In addition, column chromatography using a C18 column was used instead of the purification method. (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS[M+H]=m / z 489.3

[1059]

[1060] Preparation of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-(2-morpholinoacetyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate, except that morpholin-4-ylacetic acid was used instead of N-(tert-butoxycarbonyl)glycine. In addition, the purification method was replaced by column chromatography using a C18 column. (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS [M+H] = m / z 505.3

[1061]

[1062] Preparation of N-((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)acetamide: Follow the procedure for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)acetamide. The title compound was prepared by the same procedure as described above with respect to (R)-8-(L-alanyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used. LC / MS [M+H] = m / z 475.2

[1063]

[1064] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-nicotinoyl-2-oxa-8-azaspiro[4.5]decan-1-one: According to the method for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)methanesulfonamide The title compound was prepared by the same method except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and nicotinoyl chloride hydrochloride was used instead of methanesulfonyl chloride. LC / MS [M+H] = m / z 467.2

[1065]

[1066] Preparation of (R)-8-(2-(1H-tetrazolyl-5-yl)acetyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one carboxylate: The title compound was prepared according to the procedure used for (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(pyridazine-3-carbonyl)-2-oxa-8-azaspiro[4.5]decan-1-one, except that 2H-tetrazolyl-5-acetic acid was used instead of 3-pyridazinecarboxylic acid. In addition, the purification method was replaced by column chromatography using a C18 column. (ACN / H2O, 0% to 100%, w / 0.1% HCOOH). LC / MS [M+H] = m / z 472.2

[1067]

[1068] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(2-(2-oxooxazolidin-3-yl)acetyl)-2-oxa-8-azaspiro[4.5]decan-1-one: According to the method for tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate The title compound was prepared by the same method as above, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and (2-oxo-1,3-oxazolidin-3-yl)acetic acid was used instead of N-(tert-butoxycarbonyl)glycine. In addition, the purification method was replaced by column chromatography using a C18 column. (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS[M+H]=m / z 489.3

[1069]

[1070] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(pyridazine-3-carbonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The reaction was carried out in oven-dried glassware under nitrogen atmosphere. 3-Pyridazinecarboxylic acid (14.3 mg, 0.115 mmol, 1.9 eq) was added to a vial and dissolved in dimethylacetamide (500 μL). Next, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (55.8 mg, 0.291 mmol, 4.8 eq), 1-benzotriazole (39.3 mg, 0.291 mmol, 4.8 eq) and N-methylmorpholine (59 mg, 0.584 mmol, 9.6 eq) were added and the resulting solution was stirred at 23° C. for 15 minutes. Next, (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (21.9 mg, 0.0607 mmol, 1 eq) was added, using dimethylacetamide (150 μL) to assist the transfer. The resulting solution was stirred at 23°C for 30 minutes, then diluted with methanol (5 mL) and concentrated in vacuo. The resulting residue was suspended in saturated NaHCO3 (5 mL) and extracted with dichloromethane (3×10 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the crude product, which was further purified by C18 column chromatography (ACN / H2O, 0% to 100%, w / 0.1% NH4OH). LC / MS[M+H]=m / z 468.2

[1071]

[1072] Preparation of (R)-8-acetyl-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: Prepare (R)-8-acetyl-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one according to the method for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl The title compound was prepared by the same procedure as described above with respect to 4-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used. LC / MS [M+H] = m / z 418.2

[1073]

[1074] Preparation of N-((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)acetamide: Follow the procedure for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2 The title compound was prepared by the same procedure as described above with respect to 4-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that (R)-8-((S)-2-aminobutyryl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 489.2

[1075]

[1076] Preparation of N-((S)-1-((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)acetamide: Follow the procedure for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)acetamide. The title compound was prepared by the same procedure as described above except that (R)-8-(L-valyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 502.2

[1077]

[1078] Preparation of (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid methyl ester: Prepare (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-yl)-2-oxoethyl)acetamide according to the method for The title compound was prepared by the same procedure as described above, except that (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and methyl chloroformate was used instead of acetyl chloride. LC / MS [M+H] = m / z 434.2

[1079]

[1080] Preparation of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(isoxazol-3-yl)-2-oxa-8-azaspiro[4.5]decan-1-one: The reaction was carried out in oven-dried glassware under nitrogen atmosphere. To a solution of (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (1.0 g, 2.76 mmol, 1.0 equiv) and 3-bromoisoxazole (0.614 g, 4.15 mmol, 1.5 equiv) in anhydrous toluene (10.6 mL) were added the following in this order: Pd2(dba)3 (0.063 g, 5 mol%), BINAP (0.127 g, 7.5 mol%), triethylamine (0.698 g, 6.6 mmol, 2.5 equiv) and NaOtBu (0.291 g, 3.3 mmol, 1.2 equiv). The resulting mixture was stirred at 80 °C under N2 purge overnight. The reaction mixture was cooled to room temperature and then filtered through a plug of celite. The collected filtrate was concentrated in vacuo to give a crude residue which was further purified by column chromatography (dichloromethane / methanol, 0%-10%). LC / MS [M+H] = m / z 429.3

[1081]

[1082] Preparation of (R)-(2-(3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate: Prepare the following steps according to the method for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate: The title compound was prepared by the same procedure as acetamide, except that (R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride was used instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride and methyl chloroformate was used instead of acetyl chloride. LC / MS [M+H] = m / z 477.2

[1083]

[1084] Preparation of (R)-3,3-diethyl-5-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)dihydrofuran-2(3H)-one: The title compound was prepared according to the procedure for tert-butyl (R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except that tert-butyl (R)-2-(4,4-diethyl-5-oxotetrahydrofuran-2-yl)ethyl 4-methylbenzenesulfonate was used in place of tert-butyl (R)-1-oxo-3-(2-(tosyloxy)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate. LC / MS [M+H] = m / z 363.2

[1085]

[1086] Preparation of N-((S)-1-((R)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)acetamide: Follow the procedure for (R)-N-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)acetamide. The title compound was prepared by the same procedure as (R)-8-(L-alanyl)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one instead of (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride. LC / MS [M+H] = m / z 489.2

[1087]

[1088] Preparation of (R)-8-(L-alanyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure used for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that ((S)-1-(( (R)-tert-butyl (2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)carbamate was substituted for (R)-tert-butyl (2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. In addition, the product was obtained by stirring a solution with Amberlite IRN-78 base resin in methanol for 15 minutes, then filtering and concentrating in vacuo. LC / MS [M+H] = m / z 433.2

[1089]

[1090] Preparation of (R)-8-((S)-2-aminobutyryl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure used for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that ((S)-1 -tert-butyl ((R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)carbamate instead of tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. In addition, the product was obtained by stirring a solution with Amberlite IRN-78 base resin in methanol for 15 minutes, then filtering and concentrating in vacuo. LC / MS [M+H] = m / z 447.2

[1091]

[1092] Preparation of (R)-8-(L-valyl)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that ((S)-1-((R)- tert-Butyl 3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)carbamate was used instead of tert-butyl (R)-(2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl)carbamate. In addition, the product was obtained by stirring a solution with Amberlite IRN-78 base resin in methanol for 15 minutes, then filtering and concentrating in vacuo. LC / MS [M+H] = m / z 461.2

[1093]

[1094] Preparation of (R)-8-(L-alanyl)-3-(2-((S)-4-(4-fluorophenyl)-2-methylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure used for (R)-3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-8-glycyl-2-oxa-8-azaspiro[4.5]decan-1-one dihydrochloride, except that ((S)-1-(( (R)-tert-butyl (2-(3-(2-(4-(3-chlorophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl)-1-oxopropan-2-yl)carbamate. In addition, the product was obtained by stirring a solution of Amberlite IRN-78 base resin in methanol for 15 minutes, then filtering and concentrating in vacuo. LC / MS [M+H] = m / z 447.2

[1095] Biochemical research

[1096] The biological activity of the compounds described herein can be determined according to methods known in the art, including as described in International Application No. PCT / US19 / 31824, which is incorporated herein by reference in its entirety. Exemplary assays are described herein.

[1097] method:

[1098] 1 Radiolabeled conjugate (IC 50 and K I )

[1099] Solutions of the disclosed compounds to be tested were prepared as 1 mg / ml stock solutions in assay buffer or DMSO, depending on their solubility. A similar stock solution of the reference compound chlorpromazine was also prepared as a positive control. Eleven dilutions (5x assay concentration) of the disclosed compounds and chlorpromazine were prepared in assay buffer by serial dilution to give final corresponding assay concentrations in the range of 10 pM to 10 μM.

[1100] A stock concentration of 5 nM was prepared in 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA (pH 7.4, assay buffer) 3H]LSD (lysergic acid diethylamide). Aliquots (50 μl) of the radioligand were dispensed into wells of a 96-well plate containing 100 μl of assay buffer. Serial dilutions of the disclosed test compounds and the chlorpromazine positive control reference compound were added in duplicate in 50 μl aliquots.

[1101] The membrane fraction (50 μL) of cells expressing recombinant 5-HT7 receptors was dispensed into each well. The monolayer was collected by washing with PBS, resuspending and lysing in chilled hypotonic 50 mM Tris-HCl (pH 7.4), centrifuging at 20,000 x g, decanting the supernatant and storing at -80 °C. 0 Membranes were prepared from stably transfected cell lines expressing the 5-HT7 receptor cultured on 10 cm plates at 4 °C; membrane preparations were resuspended in 3 ml of chilled assay buffer and homogenized by several passages through a 26-gauge needle before use in the assay.

[1102] 250 μl of the reaction was incubated at room temperature for 1.5 hours and then collected by rapid filtration onto a 0.3% polyethyleneimine treated 96-well filter mat using a 96-well Filtermate harvester. Four rapid 500 μl washes with chilled assay buffer were performed to reduce nonspecific binding. The filter mat was dried and scintillant was then added to the filter and the radioactivity retained on the filter was counted in a Microbeta scintillation counter.

[1103] Raw data (dpm) representing total radioligand binding (i.e., specific and nonspecific binding) were plotted as a function of the logarithm of the molar concentration of the competitor (i.e., test or reference compound). Nonlinear regression of the normalized (i.e., percent radioligand binding compared to that observed in the absence of test or reference compound) raw data was performed in Prism 4.0 (GraphPad Software) using a built-in three-parameter logistic model describing ligand competition binding to radioligand-labeled sites:

[1104] y = bottom + [(top - bottom) / (1 + 10x - logIC 50 )]

[1105] where the bottom equals the residual radioligand binding (i.e., nonspecific binding) measured in the presence of 10 μM reference compound and the top equals the total radioligand binding observed in the absence of competitor. Thus, the log IC is estimated from the data 50 (i.e., the logarithm of the ligand concentration that reduces radioligand binding by 50%) and is used to obtain Ki by applying the Cheng-Prusoff approximation:

[1106] Ki=IC50 / (1+[ligand] / KD)

[1107] where [ligand] equals the assayed radioligand concentration, and KD equals the affinity constant of the radioligand for the target receptor.

[1108] Functional data (K b )

[1109] In a cell-based cAMP enzyme fragment complementation assay, the HitHunter cAMP assay (DiscoveRx) was used to measure the efficacy of the disclosed compounds on the 5-HT7 serotonin receptor. Cells stably expressing the human 5HT7 receptor were plated in 96-well plates at 4000 cells / well 16-20 hours before the assay in growth medium (Ultraculture medium, 2mM GlutaMax and G418 1mg / mL). Serial dilutions of the agonist 5-hydroxytryptamine (5-HT) were prepared to a final concentration range of 10μM to 10nM. The disclosed compounds were prepared into 3-fold serial dilutions to obtain a final concentration range of 10μM to 0.1nM. The disclosed compounds were tested for their agonist activity in the absence of 5-HT and their antagonist activity in the presence of 5-HT. For the cAMP assay, the protocol was performed according to the instructions provided by the supplier. In brief, after adding EC 70 The cells were incubated with the disclosed compounds at 37°C for 30 minutes before adding 5-HT at a concentration of 1:1. After another 30 minutes, cAMP antibody / cell lysate (20 μL / well) was added and incubated at room temperature for 60 minutes. cAMP XS+EA reagent (20 μL / well) was added and incubated at room temperature for 2 hours. Luminescence values ​​were read on an Envision Multilabel plate reader.

[1110] Exemplary K values ​​for certain compounds according to the formulae described herein (eg, according to formula (I)-(II), such as any one of formula (A)-(AAA)) are provided in Table 1. i and K b data.

[1111] Although many embodiments of the present invention have been described, it is apparent that the basic examples can be changed to provide other embodiments utilizing the compounds, methods and processes of the present invention. Therefore, it should be understood that the scope of the present invention is defined by the appended claims rather than by the specific embodiments represented by way of example herein.

Claims

1. A compound having a structure according to formula (I*), Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: R 1N Selected from the group consisting of: imidazole, oxazole, isoxazole in Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen; R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups; Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl; R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms; R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; Each R AA are independently C1-C7 straight chain alkyl groups; Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN; a is 0, 1, or 2; aa is 0, 1 or 2; y 1 is 0, 1, or 2; and When R 5 When it is an unsubstituted C1-C7 alkyl group or an unsubstituted C3-C7 cycloalkyl group, a is 1 or 2.

2. A compound having a structure according to formula (I*-N), Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: R 1N-N Selected from the group consisting of: C6-C 10 Heteroaryl, five- to ten-membered heteroaryl, in Each R 4a and R 4b is hydrogen or C1-C7 alkyl; or R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen; R 5 Selected from the group consisting of C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups; Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl; R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms; R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; Each R AA are independently C1-C7 straight chain alkyl groups; Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN; a is 0, 1, or 2; aa is 0, 1 or 2; y 1 is 0, 1, or 2; and When R 5 When it is an unsubstituted C1-C7 alkyl group or an unsubstituted C3-C7 cycloalkyl group, a is 1 or 2.

3. The compound according to claim 1 or 2, having a structure according to formula (I*-1), Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

4. The compound according to claim 1 or 2, having a structure according to formula (I*-2), Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

5. The compound according to claim 2, having a structure according to formula (I*-3), Included are enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.

6. The compound of claim 1, wherein R 1N for: Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; 7. The compound of claim 1, wherein R 1N for: Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl; Where R 8h is an unsubstituted C1-C7 alkyl group; or 8. The compound of claim 1, wherein R 1N for: Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl; Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e is an unsubstituted C1-C7 alkyl group; Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h is an unsubstituted C1-C7 alkyl group; Where R 8h is an unsubstituted C1-C7 alkyl group; Each R 8a , R 8b , and R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h is an unsubstituted C1-C7 alkyl group; Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl; Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl; Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h are independently unsubstituted C1-C7 alkyl; or 9. The compound of claim 1, wherein R 1N for:

10. The compound of claim 1, wherein R 1N for:

11. A compound having a structure according to formula (I**), Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: Each R aa and R bb selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 branched alkyl; Each R AA are independently C1-C7 straight chain alkyl groups; Each R 2a are independently halogen, unsubstituted C1-C7 alkyl, C1-C7 perhaloalkyl, unsubstituted C1-C7 alkoxy, C1-C7 perhaloalkoxy or CN; aa is 0, 1, or 2; and a' is 1 or 2.

12. The compound of claim 11, wherein R aa and R bb Each is an ethyl group.

13. The compound of any one of claims 1-10, wherein a is 0 or 1.

14. A compound as described in any one of claims 1 to 10, wherein a is 1 or 2, and each R AA It is methyl.

15. The compound of claim 11 or 12, wherein a' is 1 or 2, and each R AA It is methyl.

16. The compound of any one of claims 1-15, wherein aa is 1 or 2.

17. The compound of claim 16, wherein each R 2a are independently halogen.

18. The compound of claim 17, wherein each R 2a is independently –F or –Cl.

19. The compound of any one of claims 1 to 18, wherein the C5 carbon of 2-dihydrofuranone has the (R)-configuration.

20. The compound of any one of claims 1-18, wherein the C5 carbon of 2-dihydrofuranone has the (S)-configuration.

21. A compound having a structure according to formula (I) Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: Each R a and R b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 branched alkyl; or R a and R b Together with the atoms to which they are attached, they form a carbocyclic ring having 5 to 7 ring atoms, optionally containing a double bond; or R a and R b Together with the atoms to which they are attached, they form a ring having 6-8 ring atoms, the ring comprising a member selected from O, S, SO, SO2 and NR 1 part of; A is an N-linked five to twelve membered nitrogen-containing heterocyclic group, wherein the nitrogen-containing heterocyclic group is bicyclic or polycyclic and optionally contains other heteroatoms selected from O, N and S, and wherein the non-aromatic nitrogen-containing heterocyclic group further contains a group R 2 ; R 1 is H, C1-C7 alkyl, C3-C7 cycloalkyl, phenyl, benzyl, a five-membered to six-membered heteroaryl ring, a polar acyl group or a polar sulfonyl group; R 2 is selected from the group consisting of a 6- to 10-membered aryl group, a 5- to 10-membered nitrogen-containing heteroaryl group, and R 3 is a 6- to 10-membered aryl group or a 5- to 10-membered nitrogen-containing heteroaryl group; m is 1, 2 or 3; and n is 1, 2, 3 or 4; and When A is 1,2,3,4-tetrahydroquinolin-1-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, octahydropyrrolo[3,4-c]pyrrol-1-yl or 2,6-diazaspiro[3.3]hept-1-yl, then R a and R b cannot be all methyl, all ethyl, or all phenyl, and R a and R b Nor can they combine to form unsubstituted C3-C6 cycloalkyl groups.

22. The compound of claim 21, having one of the following structures:

23. The compound of claim 21 or 22, wherein R a and R b are methyl or ethyl, or R a and R b Combine to form unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

24. The compound of claim 23, having one of the following structures:

25. The compound of claim 24, having one of the following structures:

26. The compound of claim 21 or 22, wherein R a and R b Together with the atoms to which they are bound they form a ring having 6 to 8 ring atoms.

27. The compound according to claim 26, having a structure according to formula (IF), 28. The compound of claim 26, having a structure according to any one of the following formulae:

29. The compound of any one of claims 21-28, wherein A is selected from the group consisting of: in R 2 Selected from the group consisting of phenyl, naphthyl, pyridyl, indolyl and R 3 selected from the group consisting of phenyl, naphthyl, pyridyl and indolyl; R A Selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl , carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups, each of which contains 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; and a is independently 0, 1 or 2.

30. The compound of claim 29, wherein A is selected from the group consisting of:

31. The compound of claim 29, wherein A is selected from the group consisting of:

32. A compound according to any one of claims 21-31, wherein R 1 Selected from the group consisting of: H, C1-C7 alkyl, C3-C7 cycloalkyl, phenyl, benzyl, imidazole, oxazole, isoxazole, Each R 4a ,R 4b ,R 4c ,R 6a ,R 6b and R 6c selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen; R 6a and R 6b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen; Each R 4d and R 6d selected from the group consisting of phenyl, benzyl, pyridyl, -CH2(pyridyl), imidazole, and -CH2(imidazole); R 5 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and R 7 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NHCONR 8f ; Each R 8a , R 8b , R 8d , R 8g and R 8i selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups; Each R 8c , R 8e , R 8f and R 8h is C1–C7 alkyl or C3–C7 cycloalkyl; R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl; or When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms; R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; R 11 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; y 1 is 0, 1, or 2; and y 2 Is 0, 1, or 2.

33. The compound of claim 32, wherein R 1 Selected from the group consisting of:

34. The compound of claim 32 or 33, wherein R 1 For COOR 5 , where R 5 C6-C 10 Aryl or 5- to 10-membered heteroaryl; Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl; Where R 8h is an unsubstituted C1-C7 alkyl group; Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl; Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl; Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e is an unsubstituted C1-C7 alkyl Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h is an unsubstituted C1-C7 alkyl group; Where R 8h is an unsubstituted C1-C7 alkyl group; Each R 8a , R 8b and R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h is an unsubstituted C1-C7 alkyl group; Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl; Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h are independently unsubstituted C1-C7 alkyl; or 35. A compound having a structure according to formula (II) Including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: A 2 for R 2 is selected from the group consisting of a 6- to 10-membered aryl group, a 5- to 10-membered nitrogen-containing heteroaryl group, and R 3 is a 6- to 10-membered aryl group or a 5- to 10-membered nitrogen-containing heteroaryl group; R A Selected from the group consisting of C1-C7 straight chain alkyl, C3-C7 branched chain alkyl, C3-C7 cycloalkyl, C1-C7 straight chain alkoxy, C3-C7 branched chain alkoxy, C3-C7 cycloalkyloxy, aryloxy, C1-C7 straight chain haloalkyl, C3-C7 branched chain haloalkyl, C3-C7 cyclohaloalkyl, C2-C7 alkenyl, C2-C7 cycloalkenyl, C2-C7 alkynyl, aryl, aralkyl, nitro, hydroxy, thiol, oxo, thio, cyano, carbamoyl alkyl, carboxyl, C1-C7 alkoxycarbonyl, sulfo, halogen, C1-C7 alkylthio, arylthio, C1-C7 alkylsulfinyl, arylsulfinyl, C1-C7 alkylsulfonyl, arylsulfonyl, amino, C1-C7 acylamino, mono- or di-C1-C7 alkylamino, C3-C7 cycloalkylamino, arylamino, C2-C7 acyl, arylcarbonyl and five- to six-membered heterocyclic groups each containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen; a is 0, 1 or 2; m is 1, 2 or 3; n is 1, 2, 3 or 4; R 1’ Selected from the group consisting of: C6-C 10 Aryl, five-membered to six-membered heteroaryl ring, Each R 4a ,R 4b ,R 4c ,R 6a ,R 6b and R 6c selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; R 4a and R 4b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen; R 6a and R 6b optionally taken together with the atoms to which they are attached to form a ring containing 3 to 7 atoms, optionally containing oxygen; Each R 4d and R 6d selected from the group consisting of phenyl, benzyl, pyridyl, -CH2(pyridyl), imidazole, and -CH2(imidazole); R 5 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NR 8i COOR 8j NHCONR 8f NR 8g COR 8h and R 7 Selected from the group consisting of hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, C1-C7 alkoxy, C3-C7 cycloalkoxy, C1-C7 haloalkyl, C3-C7 cyclohaloalkyl, C1-C7 haloalkoxy, C3-C7 cyclohaloalkoxy, C6-C 10 Aryl, 5- to 10-membered heteroaryl, CN, NR 8a R 8b 、SO2R 8c NR 8d S02R 8e NHCONR 8f ; Each R 8a , R 8b , R 8d , R 8g and R 8i is selected from the group consisting of hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 aryl and 5- to 10-membered heteroaryl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 Groups; Each R 8c , R 8e , R 8f and R 8h is C1-C7 alkyl or C3-C7 cycloalkyl; or When R 4a and R 8a Both exist or R 4a and R 8g When present, these groups are optionally taken together with the atoms to which they are attached to form a ring containing 4 to 7 atoms; R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; R 11 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; y 1 is 0, 1, or 2; and y 2 is 0, 1, or 2; and Among them, when A 2 for R 2 is phenyl, R 1’ for y 2 When is 0 and n is 2, then R 7 It is not methyl, CH2SO2CH3, CH2CN, tetrahydropyranyl, phenyl, 4-substituted phenyl or 5- to 8-membered heteroaryl.

36. The compound of claim 35, having one of the following structures:

37. The compound of claim 35 or 36, wherein R 1’ For COOR 5 , where R 5 C6-C 10 Aryl or 5- to 10-membered heteroaryl; Each R 8a and R 8b is selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; or R 8a and R 8b optionally taken together with the atoms to which they are attached to form a heterocyclic ring containing 3 to 7 atoms, optionally containing a ring selected from oxygen, sulfur and NR 9 and R 9 selected from the group consisting of: hydrogen, C1-C7 alkyl, and C3-C7 cycloalkyl; Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl; Where R 8h is an unsubstituted C1-C7 alkyl group; Where R 8j Selected from the group consisting of: C1-C7 alkyl, C3-C7 cycloalkyl, C6-C 10 Aryl and 5- to 10-membered heteroaryl; Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl; Where R 8d are independently H or unsubstituted C1-C7 alkyl, and R 8e is an unsubstituted C1-C7 alkyl Where R 4a and R 8g are each independently H or unsubstituted C1-C7 alkyl; and R 8h is an unsubstituted C1-C7 alkyl group; Where R 8h is an unsubstituted C1-C7 alkyl group; Each R 8a , R 8b and R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h is an unsubstituted C1-C7 alkyl group; Each R 8a and R 8b are independently H or unsubstituted C1-C7 alkyl; Where R 8g are independently H or unsubstituted C1-C7 alkyl, and R 8h are independently unsubstituted C1-C7 alkyl; or 38. A compound as described in any one of claims 35-37, wherein A 2 for 39. A compound as described in any one of claims 35-37, wherein A 2 for 40. A compound as described in any one of claims 35-37, wherein A 2 for 41. A compound selected from the group consisting of Compounds 1-145, or a pharmaceutically acceptable salt thereof.

42. A pharmaceutical composition comprising a compound according to any one of claims 1 to 41 or a pharmaceutically acceptable salt thereof.

43. The pharmaceutical composition of claim 42, further comprising at least one pharmaceutically acceptable excipient.

44. A method for treating a disease associated with dysregulation of serotonin receptor 7 activity, the method comprising administering to a subject an effective amount of at least one compound according to any one of claims 1 to 41 or a pharmaceutically acceptable salt thereof.

45. The method of claim 44, wherein the at least one compound or a pharmaceutically acceptable salt thereof is administered in the form of a composition further comprising at least one excipient.

46. ​​The method of claim 44 or 45, wherein the disease associated with dysregulation of 5-HT receptor 7 activity is selected from the group consisting of peripheral selective diseases, nervous system diseases, circadian rhythm disorders, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral vascular disease, migraine, neuropathic pain, peripheral pain, allodynia, temperature regulation disorders, learning disorders, memory disorders, hippocampal signaling disorders, sleep disorders, attention deficit / hyperactivity disorder, anxiety disorders, avoidant personality disorder, premature ejaculation, eating disorders, premenstrual syndrome, premenstrual dysphoric disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), enteritis, epilepsy, epileptic diseases, drug addiction, alcohol addiction, breast cancer, liver fibrosis, chronic liver injury, hepatocellular carcinoma, small intestinal neuroendocrine tumors and lung injury.

47. The method of claim 44 or 45, wherein the disease associated with dysregulated serotonin receptor 7 activity is inflammatory bowel disease (IBD) or inflammatory bowel disease.